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Depletion of endoplasmic reticulum (ER)
calcium can lead to the loss of resident
proteins in a process termed exodosis.
Henderson et al. performed a high-
throughput screen for compounds that
attenuate exodosis and identify clinically
approved drugs, including bromocriptine.
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SUMMARY
Endoplasmic reticulum (ER) dysregulation is associated with pathologies including neurodegenerative,
muscular, and diabetic conditions. Depletion of ER calcium can lead to the loss of resident proteins in a pro-
cess termed exodosis. To identify compounds that attenuate the redistribution of ER proteins under path-
ological conditions, we performed a quantitative high-throughput screen using the Gaussia luciferase
(GLuc)-secreted ER calciummodulated protein (SERCaMP) assay, whichmonitors secretion of ER-resident
proteins triggered by calcium depletion. We identify several clinically used drugs, including bromocriptine,
and further characterize them using assays to measure effects on ER calcium, ER stress, and ER exodosis.
Bromocriptine elicits protective effects in cell-based models of exodosis as well as in vivomodels of stroke
and diabetes. Bromocriptine analogs with reduced dopamine receptor activity retain similar efficacy in sta-
bilizing the ER proteome, indicating a non-canonical mechanism of action. This study describes a strategic
approach to identify small-molecule drugs capable of improving ER proteostasis in human disease condi-
tions.
INTRODUCTION
The endoplasmic reticulum (ER) and sarcoplasmic reticulum (SR)
is a site of essential cellular functions, including protein matura-
tion and trafficking, lipid synthesis and metabolism, drug catab-
olism, and calcium storage. The high concentration of calcium
within the ER lumen is needed for proper functioning of the ER
(Burdakov et al., 2005; Fu et al., 2012), and dysregulation of ER
calcium can trigger an ER stress response that leads to cell
death if unresolved (Metcalf et al., 2020). The diverse processes
of the ER are catalyzed by resident luminal proteins that contain
a carboxy-terminal ER retention sequence (ERS). If ER resident
proteins move from the ER to Golgi, the ERS is recognized by
a KDEL receptor (KDELR) that initiates retrograde transport to
return the proteins to the ER lumen (Munro and Pelham, 1987;
Semenza et al., 1990). We recently discovered that ER calcium
depletion causes ER resident proteins (e.g., chaperones, isom-
erases, etc.) to escape the KDELR retrieval pathway and be
secreted from the cell. The massive departure of ER resident
proteins from the cell or ‘‘exodosis’’ is a process that appears
to contribute to a variety of disease states associated with ER
calcium depletion (Trychta et al., 2018a).
ER stress and ER calcium dysregulation are observed in
diverse pathologies, including pancreatic (diabetes andWolfram
syndrome), neuronal (Alzheimer’s, Huntington’s, and Parkin-
son’s diseases and Wolfram syndrome), cardiovascular (chronic
heart failure, atherosclerosis, and diabetic cardiomyopathy),
muscular (Brody disease and central core disease), and viral
(hepatitis C, human cytomegalovirus, and rotavirus) diseases
(Hetz et al., 2020; Mekahli et al., 2011). Monogenic diseases,
such as Brody myopathy (SERCA1 [MIM: 601003]), Darier dis-
ease (SERCA2 [MIM: 124200]), ryanodine-receptor-1-related
myopathies (MIM: 180901), and Wolfram syndrome (Wolfram
syndrome 1 [WFS1] [MIM: 222300]), have a defined connection
between ER calcium depletion and pathogenesis (Lu et al.,
2014). Other diseases exhibit a more-complex etiology, where
the relationships between ER calcium dysfunction and disease
progression are not fully understood. Heart failure, for instance,
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Figure 1. High-throughput screening (HTS) approach to identify small molecules that stabilize ER resident proteins
(A) Schematic of SERCaMP-based HTS approach. Cells were pre-treated with compound for 16 h before the addition of 100 nM thapsigargin. Compounds that
stabilize ER calcium or augment KDELR retrieval should decrease SERCaMP release.
(B) GLuc-SERCaMP is secreted in response to thapsigargin treatment. Reporter cells (or GLuc control cells) were seeded in 1,536-well format, and GLuc activity
wasmeasured after 4 h of thapsigargin treatment (n = 2 per concentration). Thapsigargin half maximal effective concentration (EC50) = 112 nM inGLuc-SERCaMP
cells.
(legend continued on next page)




is associatedwith decreased (sarcoplasmic/endoplasmic reticu-
lum calcium ATPase (SERCA) activity (Dash et al., 2001; Piacen-
tino et al., 2003) and increased calcium efflux through the ryano-
dine receptor (RyR) (Marx et al., 2000); however, whether these
molecular events drive myopathy or are a downstream effect is
unclear. For both monogenic and complex diseases associated
with ER calcium dysfunction, pursuing approaches that restore
and maintain ER homeostasis provides opportunities to charac-
terize pathogenesis and develop therapeutics.
We postulated that a target-agnostic phenotypic screen for
small-molecule modulators of ER exodosis would identify a set
of compounds that could be used to improve outcome in disease
models where ER calcium and ER proteostasis are disrupted.
Toward this goal, we performed a quantitative high-throughput
screen using the secreted ER calcium modulated protein (SER-
CaMP) technology. SERCaMP was initially developed as a re-
porter of ER calcium homeostasis using a Gaussia luciferase
with amodified signal peptide and carboxy terminus (C terminus)
(GLuc-SERCaMP), modifications that confer secretion of the re-
porter in response to ER calcium depletion (Henderson et al.,
2014). The assay was used to screen 9,501 compounds,
including a collection of drugs approved by the FDA (US), EMA
(EU), NHI (Japan), and HC (Canada) regulatory agencies (Huang
et al., 2011). Because the SERCaMP reporter reflects the exodo-
sis phenomenon (Trychta et al., 2018a), compounds identified in
the screen have the potential to prevent exodosis by different
mechanisms, such as stabilizing ER calcium, reducing antero-
grade movement, or augmenting ERS retrieval from the Golgi
to the ER. Here, we describe the characterization of several
approved drugs identified in this screen that help retain resident
proteins of the ER. These studies provide the foundation for
future efforts aimed at further characterizing the in vivo efficacy
of drugs that stabilize the resident ER proteome. Additionally,
we identified several approved drugs that could potentially be re-
purposed for indications associated with ER calcium depletion
and exodosis.
RESULTS
High-throughput screening and orthogonal assays
identify small-molecule modulators of exodosis
The previously described SERCaMP assay can be used to
monitor the release of ER-localized proteins (referred to as exodo-
sis) in response to ERcalciumdepletion bymeasuring secretion of
a reporter from as few as 20 cells (Henderson et al., 2014). We
adapted this assay to perform a quantitative high-throughput
screen (qHTS) for small-molecule modulators of ER exodosis us-
ing SH-SY5Y human neuroblastoma cells stably expressing
GLuc-SERCaMP. After pre-treating cells for 16 h with candidate
compounds, thapsigargin (Tg) was added to inhibit SERCA,
deplete the ER calcium store, and trigger exodosis (Figure 1A).
We anticipated that anti-exodosis compounds would reduce
GLuc-SERCaMP secretion and could be identified by measuring
luciferase activity in the medium. The GLuc-SERCaMP assay
was miniaturized to 1,536-well format, and the luciferase sub-
strate (coelenterazine [CTZ]) was added directly to wells contain-
ing cells to measure extracellular GLuc. Under these conditions,
the luminescent signal was almost entirely attributable to extracel-
lular, not intracellular, luciferase (Figures S1A and S1B). GLuc-
SERCaMP-expressing cells showed a dose-dependent release
of the reporter in response to thapsigargin, whereas the cells ex-
pressing an unmodified GLuc control reporter were unaffected by
thapsigargin (Figure 1B). Dantrolene, a well-characterized RyR
antagonist that was previously shown to attenuate Tg-induced
SERCaMP release (Henderson et al., 2014), was tested using
compound sourced from five vendors (Figure 1C). Each of the
dantrolene samples reduced SERCaMP release with a half
maximal inhibitory concentration (IC50) values ranging from 12 to
69 mM, consistent with reported plasma levels at effective thera-
peutic doses used to treat malignant hyperthermia (Flewellen
et al., 1983). A screen of 9,501 compounds (14,689 samples; Ta-
ble S1), including a collection of approximately 2,500 drugs
approved for use in humans, was performed at three concentra-
tions (1.5, 7.7, and 38.3 mM). Assay performance was deemed
acceptable for screening, with a median Z’ factor 0.51 (mean =
0.36) for thapsigargin-induced SERCaMP release (Figure S1C).
The 578 compounds that demonstrated inhibitory activity in the
primary screen (Table S1) were sourced and re-tested at 11 con-
centrations (1.3 nM–76.6 mM). Of the 578 compounds, 315 com-
pounds (54%; Table S2) were confirmed in the follow-up SER-
CaMP assay (Figure 1D).
A decrease in SERCaMP release, although suggestive of
improved ER proteostasis, would also be expected for small
molecules that inhibit the secretory pathway, transgene expres-
sion, or cell viability. Therefore, active compounds from the
primary screen were counterscreened using (1) SH-SY5Y cells
(C) The RyR antagonist dantrolene inhibits GLuc-SERCaMP release. Cells were pre-treatedwith dantrolene (from five vendors) for 16 h, andGLuc-SERCaMPwas
measured in the medium 4 h after 100 nM thapsigargin treatment.
(D) 578 compounds identified in the 3-concentration primary screen (of 9,501 compounds) were re-tested at 11 concentrations.Waterfall plot depicts inhibition of
GLuc-SERCaMP after 4 h treatment with thapsigargin. Compounds are grouped into the following classes of inhibitors: full (>80% inhibition; curve class 1.1,
2.1; green); partial (<80% inhibition; curve class 1.2, 2.2; yellow); or inactives and lower confidence curves (red).
(E) Diagram of the screening approach, outlining the primary screen, counterscreens, and orthogonal assays used to identify compounds that stabilize ER
resident proteins.
(F) GLuc counterscreen (constitutively secreted reporter) to identify compounds that alter secretory pathway function. The ER-to-Golgi transport inhibitor
brefeldin A was added to cells for 19 h. Dose-response curves for brefeldin A were generated for eight 1,536-well plates from the counterscreen (mean; n = 2 per
concentration).
(G) Waterfall plot summarizing activity of 578 hit compounds in the constitutively secreted GLuc counterscreen (SH-SY5Y-GLuc-NoTag; 19 h treatment). Active
(inhibits secretion, red) and inactive (no effect on secretion, green) compounds are shown.
(H) Waterfall plot summarizing cytotoxicity counterscreen. SH-SY5Y-GLuc-SERCaMP viability was assessed by CellTiter Glo after 43 h compound treatment.
Cytotoxic compounds (red) and inactive compounds (green) are indicated.
See also Figure S1.




stably expressing a constitutively secreted GLuc (SH-SY5Y-
GLuc) to assess effects on secretory capacity and transgene
expression and (2) a CellTiter Glo assay to examine viability (Fig-
ure 1E). For the SH-SY5Y-GLuc counterscreen, the ER-to-Golgi
transport inhibitor brefeldin A was used as a positive control (Fig-
ure 1F). Of the 315 confirmed SERCaMP actives, 68 compounds
(22%; Table S2; Figure S1F) showed inhibitory activity in the SH-
SY5Y-GLuc counterscreen (Figure 1G), including cycloheximide,
a protein synthesis inhibitor (Figure S1D). For the cell viability
counterscreen, the cytotoxic proteasome inhibitor bortezomib
was used as a positive control (Figure S1E). The viability counter-
screen identified 82 compounds (26%; Table S2; Figure S1F) as
cytotoxic at 42 h (Figure 1H). Following the counterscreens, 185
compounds from the initial 578 (32%; Table S2)met the following
criteria: (1) confirmed in the primary SERCaMP assay; (2) did not
exhibit activity in the GLuc counterscreen; and (3) did not show
toxicity in the cell viability assay.
Of the 185 remaining actives, 71 compounds have a develop-
mental status (according to National Center for Advancing
Translational Sciences [NCATS] portal for drug development in-
formation; https://drugs-01.ncats.io/; Table S1C). We focused
our efforts on five FDA-approved drugs for further assessment
(dextromethorphan, bromocriptine, dantrolene, verapamil, and
diltiazem), due to both known associations with calcium modu-
lation or secretion and the potential to be repurposed for dis-
eases where ER calcium dysregulation and exodosis have
been detected (Figure 2A). To confirm the screening results,
the compounds were tested in 96-well format for SERCaMP ac-
tivity (Figure 2B), inhibition of the secretory pathway (Figure S2A),
and effects on cell viability (Figure S2B). These experiments
confirmed the results from the qHTS, supporting potential activ-
ity on stabilizing the ER proteome. We predicted that com-
pounds acting directly on ER calcium regulators, e.g., RyR and
inositol triphosphate (IP3R) would retain activity when tested in
an acute treatment paradigm. All five compounds inhibited SER-
CaMP release when added 30 min pre- to 2 h post-thapsigargin
but were inactive when added 4 h post-thapsigargin (Figures 2C
and S2C–S2G), supporting a rapid effect on exodosis and not a
preconditioning effect.
We hypothesized that some compounds prevent exodosis by
directly stabilizing ER calcium and utilized the genetically en-
coded calcium monitoring protein of the ER or GCaMPer (Hen-
derson et al., 2015a), to examine ER calcium dynamics after
drug treatment. GCaMPer has low-affinity calcium-binding do-
mains and shows reduced fluorescence as the ER calcium store
is depleted. SERCA inhibition with Tg decreased GCaMPer fluo-
rescence in SH-SY5Y cells (Figure 2D), and the effect of com-
pounds (16 h pre-treatment) on GCaMPer fluorescence was
examined. Bromocriptine and verapamil showed a stabilizing ef-
fect on ER calcium, whereas dextromethorphan and diltiazem
showed no effect (Figure 2E). Dantrolene was not assessed, as
it produces fluorescence that overlaps with the spectral proper-
ties of GCaMP-based reporters (Dehpour et al., 1982).
One of the major consequences of Tg treatment is the activa-
tion of the unfolded protein response (UPR). We predicted that
some compounds identified in the screen would also alter the
UPR. ATF6 and IRE1 signaling, which are activated by ER stress,
were examined using a reporter containing UPR transcriptional
elements (UPRE) driving NanoLuc (NLuc) expression (Wires
et al., 2017). SH-SY5Y cells were transiently transfected with
UPRE-NLuc, and thapsigargin-induced expression of the re-
porter was confirmed (Figure 3A). Bromocriptine, verapamil,
and dextromethorphan diminished UPRE-NLuc activation,
whereas dantrolene and diltiazemwere inactive in the assay (Fig-
ure 3B). The compounds showed no effects on NLuc activity
when applied to cells transfected with a control construct con-
taining a minimal promoter lacking the UPRE (Figure S3A).
Next, we examined endogenous UPR genes by measuring BiP
(immunoglobulin heavy chain-binding protein), ERdj4, and
ASNS (asparagine synthetase) mRNA levels to assess the
ATF6 (activating transcription factor 6), XBP1 (X-Box binding
protein 1), and PERK (protein kinaseRNA-like endoplasmic retic-
ulum kinase) arms of the UPR, respectively. Bromocriptine and
verapamil treatment reduced expression of BiP, whereas the
other compounds did not significantly alter transcript levels (Fig-
ure 3C). ERdj4 and ASNS were not significantly altered by any of
the compounds. Furthermore, compound treatment alone did
not have any effect on BiP, ERdj4, or ASNS mRNA expression
(Figure S3B). BiP/GRP78 protein levels were also examined,
and bromocriptine and verapamil reduced thapsigargin-induced
accumulation (Figures 3D and 3E).
Anti-exodosis activity of compounds examined using
in vitro models of ER/SR calcium depletion
Next, we sought to model exodosis caused by ER calcium
depletion in disease-relevant contexts. Toward monitoring other
cell types that are highly dependent on ER calcium fluctuations,
primary human skeletal muscle cells were transduced with an
AAV vector expressing GLuc-SERCaMP and treated with thapsi-
gargin to cause ER/SR calcium efflux. As expected, thapsigargin
treatment elicited a dose-dependent increase in secreted GLuc
activity (Figure 4A). Dextromethorphan, bromocriptine, dantro-
lene, verapamil, and diltiazem all partially attenuated GLuc-
SERCaMP release following a 30-min pre-treatment, with
bromocriptine and dextromethorphan having the greatest effect
(Figures 4B, S4A, and S4B). This could have implications for the
treatment of neuromuscular diseases in which ER calcium
dysfunction is observed, such as in ryanodine-receptor-isoform-
1-related myopathies (RYR1-RM).
As a second in vitromodel of exodosis triggered by ER calcium
depletion, we examined Wolfram syndrome, a rare monogenic
disorder characterized by juvenile-onset diabetes, optic nerve
atrophy, and neurodegeneration. Pathogenic variants in the
WFS1 gene, which encodes an ER-localized protein, result in
dysregulation of the ER calcium store (Lu et al., 2014; Osman
et al., 2003). We used a previously characterized rat pancreatic
beta cell model in which doxycycline-induced knockdown of
Wfs1 triggers caspase-dependent cell death (Fonseca et al.,
2015) and hypothesized the SERCaMP screening hits would
attenuate caspase activation via stabilization of ER proteome.
48 h after doxycycline treatment, markers of ER stress were
elevated in the knockdown cells (Figure 4C), but not parental
cells (Figure 4D), confirming activation of the UPR in the cell
model. Wfs1 knockdown also increased extracellular carboxy-
lesterase activity (Figure S4C), a previously identified biomarker
of ERS proteins undergoing exodosis caused by ER calcium




Figure 2. Five clinically approved drugs were selected for additional characterization
(A) Efficacy (percent inhibition of SERCaMP secretion) and potency determined in the 1,536-well assay (11 concentrations).
(B) Inhibition of GLuc-SERCaMP secretion was confirmed in 96-well format assays. Cells were treated with compound for 16 h followed by 4 h of 100 nM Tg.
Medium was collected and GLuc-SERCaMP activity measured (mean ± SEM; n = at least 3 independent experiments).
(C) Acute treatment paradigm to examine rapid effects onGLuc-SERCaMP release. Cells were treated with 30 mMof the compounds at the indicated time relative
to 200 nM thapsigargin treatment. GLuc-SERCaMPwasmeasured in themedium 8 h after thapsigargin treatment (mean ± SEM; n = 3 independent experiments).
(D) A genetically encoded ER calcium indicator (GCaMPer) was used to monitor ER calcium depletion caused by thapsigargin. Cells were treated for 30 min with
50 nM thapsigargin, and fluorescence intensity was calculated on a per cell basis (mean ± SEM; n = 75 cells per group). ***p < 0.001 (two-tailed t test).
(E) Effect of compounds on ER calcium store was assessed using GCaMPer. Compounds were added 16 h prior to 50 nM thapsigargin treatment. GCaMPer
fluorescence was measured 30 min after thapsigargin administration (mean ± SEM; n = 75 cells per group) and normalized to the thapsigargin (100% loss of
fluorescence) and vehicle (0%) controls. ***p < 0.001 (Dunnett’s multiple comparison test versus Tg only).
See also Figure S2.




depletion (Trychta et al., 2018b).Wfs-1 knockdown induced acti-
vation of caspase 3/7 (Figure 4E), and the assaywasminiaturized
to a 1,536-well format to facilitate high-throughput drug testing
(Figure S4D). Bromocriptine, verapamil, and diltiazem each
reduced caspase 3/7 activation associated with Wfs1 knock-
down (Figure 4F). We next tested the compounds in an in vitro
oxygen-glucose deprivation (OGD) model of stroke. Stroke rep-
resents a disease with a complex pathology driven by many
Figure 3. HTS compound effects on unfolded protein response (UPR) pathways
(A) A secreted reporter of UPR activity wasmeasured after 100 nMTg treatment by collectingmedium at different time points (gray bars; mean ±SEM; treated: n =
6; control: n = 18 wells; one-way ANOVA with Dunnett’s multiple comparison test; ***p % 0.001). A control reporter, lacking the 53 UPRE elements, does not
respond to thapsigargin (white bars; mean ± SEM; treated: n = 6; control: n = 18 wells).
(B) Verapamil, bromocriptine, and dextromethorphan reduce 53-UPRE-secNLuc. Cells were treated with compound for 24 h followed by an additional 24 h in the
presence of 100 nM thapsigargin. 53-UPRE-secNLuc activity was normalized to the thapsigargin-only control (mean ± SEM; n = 3 independent experiments).
(C) Quantitative RT-PCR analysis of BiP, ERdj4, and ASNSmRNA levels to assess ATF6, XBP1, and PERK signaling pathways of the UPR. Cells were pre-treated
with 30 mM compounds 16 h prior to a 4-h incubation with 100 nM thapsigargin (2ddCq ± upper and lower limits; n = 6; ***p < 0.001 and *p < 0.05 as compared to
thapsigargin only; one-way ANOVA and Dunnett’s multiple comparisons test).
(D) BiP protein levels were examined using the same treatment paradigm described for (C). Actin was immunoblotted as a loading control.
(E) Summary of BiP expression for four independent experiments described in (D) (mean ± SEM; **p < 0.01; one-way ANOVA and Dunnett’s multiple comparison
test).
See also Figure S3.
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mechanisms, including ER calcium dysregulation (Bodalia et al.,
2013; Bull et al., 2008; Trychta et al., 2018a). First, we demon-
strated that in vitro oxygen-glucose deprivation of SH-SY5Y
cells (timeline in Figure S4E) elicited a time-dependent decrease
in cell viability (Figure 4G), an increase in the exodosis phenotype
based on GLuc-SERCaMP (Figure 4H), and an increase in secre-
tion of the endogenous ERS-containing protein, mesencephalic
astrocyte derived neurotrophic factor or MANF (Figure S4F).
Dantrolene, diltiazem, and bromocriptine all improved cell
attachment and viability (Figures 4I and 4J) and decreased
GLuc-SERCaMP secretion (Figure 4K), consistent with reversal
of the exodosis phenotype. The effect of bromocriptine was
particularly compelling, given it also showed activity in the afore-
mentioned assays; therefore, we focused our efforts on further
investigating bromocriptine’s ability to attenuate exodosis.
Bromocriptine and its GPCR-defective analogs
attenuate exodosis caused by oxygen glucose
deprivation in vitro
In addition to secretion of the GLuc-SERCaMP reporter, our pre-
vious studies revealed the departure of endogenous ER resident
proteins, such as ER luminal chaperones, in response to thapsi-
gargin or oxygen-glucose deprivation, which could be partially
reversed by dantrolene administration (Trychta et al., 2018a). To
explore whether bromocriptine could similarly affect secretion of
protein with diverse ER retention sequences (ERSs), representing
resident proteins of the ER, we examined a set of 94 reporter pro-
teins that were tagged with ERS and non-ERS tails derived from
the human proteome (Table S2; Figure S5A). Bromocriptine
broadly inhibited thapsigargin-induced release of the reporter pro-
teins (Figure 5A). Furthermore, bromocriptine and dantrolene had
similar effects in the thapsigargin-induced model of ERS protein
secretion (Figure S5B). The effect on protein disulfide-isomerase
(PDI), MANF, and carboxylesterases, which represent three
endogenous ERS-containing proteins, was also examined.
Bromocriptine reduced thapsigargin-induced secretion of all three
proteins (Figures 5B–5D) but had minimal effect on their secretion
under non-stressed conditions (Figure S5C). Oxygen-glucose
deprivation also promotes an exodosis phenotype (Trychta
et al., 2018a; Figure S5A), and bromocriptine broadly reduced
the OGD-induced release of the reporter proteins (Figure 5E).
Again, the exodosis response to bromocriptine and dantrolene
exhibited similar profiles (Figure 5F), and the OGD-induced
release of carboxylesterases was decreased in bromocriptine-
treated cells (Figure 5G). In summary, these results indicate that
bromocriptine can counteract exodosis caused by ER calcium
dysfunction related to thapsigargin and oxygen-glucose depriva-
tion, similar to what was previously observed for dantrolene
(Trychta et al., 2018a).
Bromocriptine has been extensively characterized as a dopa-
mine receptor 2 (D2R/DRD2) agonist and has been used clini-
cally for hyperprolactinemia and Parkinson’s disease. In 2008,
the compoundwas approved for the treatment of type 2 diabetes
(T2D). Notably, it has been difficult to ascribe bromocriptine’s
pharmacodynamic effects in various human conditions solely
to its dopamine-related activity (Michael Besser et al., 2018).
To examine the possibility that D2R agonism was driving the
anti-exodosis phenotype, four additional D2R agonists of
different chemotypes were examined, which showed no activity
in the SERCaMP assay (Figure S6A). To more directly assess the
dopaminergic activity of bromocriptine on exodosis, we modi-
fied the molecule by placing adducts on the nitrogen atom of
indole ring of the lysergic acid portion, which we predicted would
reduce its dopamine receptor activity (analogs 686 and 688; Fig-
ure 6A). The two novel bromocriptine analogs were both equally
effective as bromocriptine in the SERCaMP assay (Figure 6B). In
contrast, the activity of the analogs was significantly right shifted
in D2R coupling assays for both b-arrestin (100- to 300-fold; Fig-
ure 6C) and Gi recruitment (40- to 100-fold; Figure 6D), confirm-
ing reduced DR2 activity. The activity of the bromocriptine
Figure 4. HTS compound activity in other in vitro models of ER/SR Ca2+ depletion
(A) Thapsigargin-induced GLuc-SERCaMP release in primary human skeletal muscle cells. Primary human skeletal muscle cells were treated with 3–300 nM
thapsigargin. GLuc-SERCaMP release was measured 8 h after thapsigargin treatment and normalized to vehicle control (mean ± SEM; n = 9–10 wells; one-way
ANOVA; Dunnett’s multiple comparison test vehicle versus Tg).
(B) Effect of compound pre-treatment on GLuc-SERCaMP release in primary human skeletal muscle cells. Luminescence was measured 8 h after 100 nM
thapsigargin treatment (mean ± SEM; n = 11–12 wells per drug concentration).
(C) Tetracycline-inducible Wfs1 knockdown in INS1 832/13 cells induces UPR. BiP, ERdj4, and ASNS transcript levels were measured 48 h after doxycycline
treatment (2ddCq ± upper and lower limits; n = 9 wells; two-way ANOVA with Sidak multiple comparisons; **p < 0.01).
(D) UPR is not induced in parental INS1 832/13 cells (n = 3 wells).
(E) Wfs1 knockdown induces caspase 3/7 activity. Cells were incubated with 2 mg/mL doxycycline for 48 h, and caspase 3/7 was measured using Caspase-Glo
Assay reagents (n = 64 wells per group).
(F) Compound effect on caspase 3/7 induction followingWfs1 knockdown. Cells were treated with compounds and doxycycline for 48 h, and caspase 3/7 activity
was measured. Values were normalized using a CellTiterGlo ATP assay to account for changes in cell viability (mean ± SEM; n = 3).
(G and H) SH-SY5Y cells were exposed to increasing duration of oxygen-glucose deprivation (OGD), followed by return to normoxic conditions for 24 h.
(G) Viability was assessed using CellTiterGlo ATP assay (mean ± SEM; normoxia: n = 18 wells; OGD time points: n = 6 wells).
(H) GLuc-SERCaMP was measured in the medium (secreted) and in lysates (intracellular), and the secreted ratio was calculated (mean ± SEM; normoxia: n = 18
wells; OGD time points: n = 6 wells).
(I) Viability after OGD (16 h hypoxia plus 24 h normoxia). All drugswere added concurrent with the beginning of OGD. CellTiterGlo luminescence was normalized to
normoxia controls (mean ± SEM; n = 6 independent experiments).
(J) Micrographs of cells after exposure to OGD (16 h hypoxia plus 24 h normoxia). All compounds were dosed at 20 mM, except dantrolene, which was used at
30 mM.
(K) GLuc-SERCaMP release was measured after OGD (16 h hypoxia plus 24 h normoxia) and normalized to vehicle-treated controls (mean ± SEM; n = 6
independent experiments).
See also Figure S4.




Figure 5. Effects of bromocriptine on ER calcium triggered release of ERS proteins (exodosis)
(A) SH-SY5Y cells were transfected with GLuc-ERS constructs and exchanged into growth media containing 1.5% BGS after 28 h. Treatments began 16 h after
the media exchange. Effects of a 30-min pre-treatment with 20 mM bromocriptine on the GLuc-ERS reporter library secretion following an 8 h treatment with
200 nM thapsigargin were measured. Each number along the x axis represents a GLuc reporter protein with an appended seven-amino-acid ERS tail that
corresponds to the C terminus of a human ER luminal protein (see Table S2 for key). This ERS tail library represents amajority of identified ERS proteins. Error bars
SEM.
(B–D) Bromocriptine (BCT) (20 mM) reduces secretion of ERS-containing proteins when applied 0.5 h before or 1 h following thapsigargin treatment (200 nM).
(B) Fold change in extracellular MANF measured using an HTRF (homogeneous time resolved fluorescence) assay (mean ± SEM; n = 9 wells; ***p < 0.001; one-
way ANOVA).
(C) Fold change in esterase activity measured using a fluorescent substrate (mean ± SEM; n = 22 wells; ***p < 0.001; one-way ANOVA).
(legend continued on next page)




analogs on other dopamine receptors (D1R, D3R, D4R, andD5R)
was also assessed using the G protein recruitment assay. Drug
response curves for all four receptors were right shifted relative
to the parent bromocriptine, consistent with lower affinity profile
of the analogs to the entire dopamine receptor family (Figures
S6B–S6E). Because bromocriptine is known to also activate
non-dopaminergic G-protein coupled receptors (GPCRs), we
screened the parent molecule and 688 analog in the National
Institute of Mental Health (NIMH) Psychoactive Drug Screening
Program (Kroeze et al., 2015), examining 320 receptors at
3 mM. Several non-dopamine receptors showed activity,
including ADRA2C (Table S3). Next, we directly compared activ-
ity of the analog and bromocriptine at concentrations ranging
from 1 pM to 30 mM for the receptors that showed the highest
activation in the single-dose screen (Figures S6F–S6O).
Compared to bromocriptine, the 688 analog had decreased af-
finity for receptors including DRD2, DRD3, ADRA2A, and
ADRA2C, but not others, including GPR34, MT1, ADORA1, and
GPR120. In light of the equipotent activity for the analogs in
the SERCaMP assay, these data support an exodosis-modu-
lating activity of bromocriptine that is not driven by the dopamine
receptor and potentially imparted via a non-GPCR target. We
next tested the analogs in the OGD model; similar to bromocrip-
tine, the analogs reduced OGD-induced secretion of GLuc-
SERCaMP (Figure 6E), improved cell viability (Figures 6F and
S6P), and reduced secretion of the ER resident protein MANF
(Figure S6Q).
Bromocriptine and its GPCR-defective analogs reduce
ischemic injury in a rodent model of stroke
The efficacy of bromocriptine against ischemic injury was exam-
ined in vivo using a transient, distal middle cerebral artery occlu-
sion (MCAO) model of stroke in rats causing a cortical injury
(Chen et al., 1986). Dantrolene and ER stress inhibitors confer pro-
tective effects in this model (Li et al., 2005), indicating a possible
connection with stabilizing the ER proteome. We first examined
the effects of dantrolene on stroke outcomes using an intracere-
broventricular injection (30 nmol in 20 mL) immediately prior to
the occlusion of the MCA. Dantrolene reduced the infarction vol-
ume and improved body asymmetry caused by a 60-min middle
cerebral artery occlusion (Figures S7A–S7C). Next, we tested
bromocriptine and the analogs (686 and 688), which we hypothe-
sized would also confer protection against ischemic injury in the
MCAO model. Compared to vehicle-injected animals, all three
compounds showed significant reduction in infarction volume,
body asymmetry, and Bederson’s neurological score (Figures
7A–7E). Analog 686 was more effective than bromocriptine at
reducing infarction volume (Figure 7C).
Comparing metabolic effects of bromocriptine and its
analog in a mouse model of diet-induced obesity
Bromocriptine is currently used clinically to treat T2D, a disease
that has been linked to ER calcium depletion (Kang et al., 2016;
Park et al., 2010). Studies support a central nervous system
(CNS)-mediated mechanism of action for bromocriptine, acting
to reset dopaminergic and sympathetic tone, although this re-
mains incompletely defined (Defronzo, 2011; Framnes-DeBoer
et al., 2020). Given the connection between ER calcium homeo-
stasis in peripheral tissues (e.g., liver and pancreas) and glucose
homeostasis, we hypothesized that bromocriptine’s effects may
also derive from its apparent non-dopaminergic effects on the ER
calcium store and exodosis. First, we assessed the pharmacoki-
netics (PK) of bromocriptine and the two analogs in plasma, liver,
pancreas, and brain. Tissue exposure was similar for the three
compounds, with highest levels detected in the pancreas (Table
S4A). Importantly, we observed minimal metabolic conversion of
analog 686 to the parent bromocriptine molecule (<1% in brain)
and no detectable conversion of analog 688. Based on these
PK results, dopaminergic agonism in the CNS is expected to
be substantially reduced for the 686 and 688 compounds, which
provided a means to test the hypothesis that bromocriptine acts
peripherally via a non-D2R mechanism. To explore this
possibility, we examined bromocriptine and analog 688 in a
high-fat-diet-induced obesity (DIO) mouse model. Animals were
placed on high-fat diet for 8 weeks and then given intraperitoneal
injections of compounds daily (12mg/kg) for 4 weekswhile main-
taining the high-fat diet. Both bromocriptine and analog 688
reduced fasting insulin and insulin resistance index (HOMA-IR)
compared to vehicle-treated animals (Figures 7F and 7G; Table
S5). Both bromocriptine and analog 688 reduced fasting glucose
levels at 4 h, but the bromocriptine group showed a larger
decrease (Table S5). Only bromocriptine reduced the glucose
excursion area under the curve (AUC) in glucose-tolerance tests,
suggesting bromocriptine was more effective at reducing hyper-
glycemia (Figures 7H and 7I). There were no significant differ-
ences in body weight, fat mass, or lean mass throughout the
experiment (Figures S7D–S7F); however, when comparing
changes in weight from week to week, bromocriptine caused a
significant decrease in body weight following the 1st week of in-
jections compared to vehicle and analog 688 (Figure 7J). At the
end of the 2nd and 3rd week of injections, food intake was
elevated in bromocriptine-injected animals relative to other
groups (Figure 7K). Cumulative caloric intake and energy expen-
diture during the 3 weeks of treatment were also significantly
higher only in the bromocriptine group (Figure S7G; Table S5).
PK analysis confirmed similar plasma levels between animals
treated with bromocriptine and analog 688 in the DIO model
(D) Secreted PDI was assessed by immunoprecipitating from cell culture media and detected by immunoblot. Western blots were quantified by densitometry
(mean ± SEM; n = 9; *p < 0.05; one-way ANOVA).
(E) Fold change in secretion of GLuc-ERS reporters following OGD (16 h hypoxia plus 24 h normoxia) without bromocriptine (mean ± SEM; n = 15 wells) or with
20 mM bromocriptine (mean ± SEM; n = 9 wells).
(F) Secretion of GLuc-ERS reporters from SH-SY5Y cells treated with dantrolene (30 mM; mean; n = 6 wells) and bromocriptine (20 mM; mean; n = 9 wells) while
exposed to OGD (16 h hypoxia plus 24 h normoxia).
(G) Bromocriptine (20 mM) attenuates the release of an esterase (ERS-containing protein) from SH-SY5Y cells following OGD (16 h hypoxia plus 24 h normoxia).
Esterase activity was measured in culture medium using a fluorogenic substrate (mean ± SEM; n = 24 wells; ***p < 0.001; two-way ANOVA).
See also Figure S5.




(Table S4B). Collectively, these data suggest that, like bromocrip-
tine, the bromocriptine analog 688 is capable of altering fasting
insulin, insulin resistance, and fasting glucose. The analog, how-
ever, did not show the transient weight loss, increased food
intake, or elevated energy expenditure that was observed with
bromocriptine.
Figure 6. Bromocriptine analogs have diminished dopamine receptor activity but retain effects on SERCaMP release
(A) Bromocriptine and two analogs modified at the nitrogen atom of indole ring of lysergic acid portion.
(B) Bromocriptine and two analogs show similar attenuation of Tg-induced SERCaMP release.
(C and D) Both analogs of bromocriptine have diminished potencies for dopamine receptor 2 activation in a (C) b-arrestin recruitment assay (mean ± SEM; n = 4)
and (D) Gi protein engagement assay (mean ± SEM; n = 12).
(E) GLuc-SERCaMP secretion in response to OGD is attenuated by 20 mM bromocriptine and analogs (mean ± SEM; n = 24 wells; ***p < 0.001; two-way ANOVA
with Dunnett’s multiple comparisons test).
(F) Micrographs were captured at the end of OGD. Scale bar is 200 mm.
See also Figure S6.




Figure 7. Bromocriptine and analogs tested in a rat model of stroke and mouse model of diet-induced obesity
(A) Representative TTC-stained rat brain slices (2 mm) showing the area of infarction 2 days following administration of bromocriptine analogs and MCAO. Red
indicates metabolically active brain areas, and white areas are indicative of infarct tissue. Scale bar is 1 cm.
(B) Quantitative analysis of the area of infarction per 2-mmbrain slice from rostral to caudal (n = 6–11 rats per each group; two-way ANOVAwith Dunnett’s multiple
comparisons test versus vehicle; **p < 0.01; ***p < 0.001). Error bars SD.
(C) Total infarct volumemeasured across slices (n = 6–11 rats; one-way ANOVAwith Dunnett’s multiple comparisons test versus vehicle; **p < 0.01; ***p < 0.001).
(D and E) Body asymmetry test (D) and Bederson’s test (E) for neurological abnormality scores were performed to assess stroke-related behaviors (n = 6–11 rats
body asymmetry and n = 4–6 rats Bederson’s test; one-way ANOVA with Dunnett’s multiple comparisons test versus vehicle; *p < 0.05; **p < 0.01; ***p < 0.001).
All data mean ± SD.
(F and G) Adult male mice on a high-fat diet for 8 weeks were injected daily (intraperitoneally [i.p.]) with vehicle, 12 mg/kg bromocriptine, or 12 mg/kg analog 688
over 3 weeks while remaining on the high-fat diet. (F) Fasting insulin and (G) insulin resistance index (HOMA-IR) were measured after 3 weeks of drug treatment.
(legend continued on next page)





Human diseases have been associated with disruptions in ER
homeostasis (Hetz et al., 2020; Mekahli et al., 2011), and thera-
peutic strategies aimed at restoring ER functions remain an
area of active investigation (Gonzalez-Teuber et al., 2019). ER
calcium dysregulation is observed in various pathologic states
(Mekahli et al., 2011), with depletion triggering the release of
ER resident proteins (Trychta et al., 2018a). We sought to identify
small molecules that could reverse this phenotype. In the most
straightforward approach, this could be accomplished by
increasing calcium uptake into the ER/SR (targeting SERCA) or
by reducing calcium efflux (targeting IP3R or RyR). These mech-
anisms have been the focus of significant research efforts, re-
sulting in clinical trials and approved drugs. Much attention has
been devoted to enhancing SERCA activity to restore ER cal-
cium homeostasis, primarily via AAV-based gene therapy.
Advanced heart failure is currently the major indication for this
approach, where increasing SERCA expression was beneficial
in both animal models and early human trials (Jessup et al.,
2011; Miyamoto et al., 2000; Prunier et al., 2008). The efficacy
of SERCA-based gene therapy, however, remains uncertain,
as the largest clinical trial (CUPID2; ClinicalTrials.gov ID
NCT01643330) reported a failure to meet primary endpoints
(Greenberg et al., 2016). Given that significant efforts have
already gone toward identifying modulators of ER calcium, our
approach was to screen for drugs that inhibit the exodosis
phenotype that arises from decreased ER calcium.
In addition to SERCA, IP3R, and RyR, there are additional
proteins and signaling pathways that modulate ER calcium dy-
namics. We hypothesized that these represent viable therapeu-
tic targets that could be identified using the SERCaMP assay,
which reports on exodosis independent of a pre-defined molec-
ular target. In addition, drugs that affect ER to Golgi transport
and the KDELR retrieval pathway may also be identified in our
screen. Because the primary screen was target agnostic, the
hit compounds were not expected to show uniform activity
across the set of orthogonal assays. For example, a compound’s
target might not be present in all cell types (e.g., beta cells versus
neurons) or modulation of a target could be insufficient to pre-
vent exodosis in a particular disease model. Therefore, the
absence of activity in an assay or model was not interpreted as
a compound lacking bona fide ER-proteome-modulating activ-
ity. The clinically approved and investigational compounds iden-
tified by our approach provide a rational starting point for further
investigation into the broad range of human pathologies associ-
ated with exodosis triggered by ER calcium depletion; this set in-
cludes 42 FDA-approved drugs (Table S1C).
Dantrolene is a RyR antagonist that stabilizes the resting state
of the channel (Choi et al., 2017) and shows protective effects in
neurodegenerative diseases associated with ER calcium
dysfunction (Sun and Wei, 2020). This compound was active in
the primary screen, which provided confidence in the ability to
detect relevant small molecules and served as a benchmark
for the in vitro and in vivo studies. Our finding that dantrolene is
protective in a stroke model is consistent with previous reports
that demonstrate RyR antagonism can reduce neuronal loss
associated with hypoxia-reperfusion injury (Boys et al., 2010),
reduce infarct volume (Hong and Chiou, 1998; Li et al., 2005),
and reduce ER stress markers (Li et al., 2005). Notably, dantro-
lene was administered acutely prior to arterial occlusion in
each of these studies; the development of treatments that are
effective in the post-stroke period are imperative, as acute pro-
phylactic care is challenging due to the unpredictable nature of
the event. A phase I study of dantrolene for the treatment of
stroke-associated spasticity found reduced clinical spasticity
and improved motor abilities, and only placebo-treated patients
continued to show signs of deterioration in phase II (Ketel and
Kolb, 1984). Given that dantrolene can stabilize ER calcium
and the ER proteome and improve cell viability following oxy-
gen-glucose deprivation (Trychta et al., 2018a), revisiting the
use of dantrolene as a post-stroke therapeutic is warranted.
The HTS also identified several clinically approved drugs that
are not known to directly bind RyR, IP3R, or SERCA. The most
potent of these was dextromethorphan, a high-affinity inhibitor
of the serotonin transporter and sigma-1 receptor, which is used
clinically for cough suppression (Taylor et al., 2016). Dextrome-
thorphan showed limited activity in the set of orthogonal assays,
so it is unclear whether this compound is a bona fide exodosis
modulator or a false positive. Sigma-1 receptor activity of dextro-
methorphan was of interest, owing to its reported ER localization
and a role in cellular calcium signaling and ER stress (Hayashi and
Su, 2007; Rosen et al., 2019). To explore this further, we tested
additional sigma-1 receptor agonists and antagonists; however,
SERCaMP response did not track with expected pharmacologic
activity (Figures S8A and S8B). Dextromethorphan has also
been linked to cellular calcium via its antagonism of both L-type
and N-type calcium channels (Carpenter et al., 1988); however,
this possible mechanism was not further explored.
Two additional L-type calcium channel antagonists identified
in the screen were verapamil and diltiazem, which are used clin-
ically to treat cardiovascular disease via their effects on the atrio-
ventricular (AV) node and smooth muscle cells lining the vascu-
lature. L-type calcium channel antagonism is expected to
decrease calcium-induced calcium release through RyR (Bodi
et al., 2005; Chavis et al., 1996), and diltiazem and verapamil
have been reported to directly inhibit RyR (Shoshan-Barmatz
et al., 1991; Valdivia et al., 1990). It was postulated that their
RyR activity was responsible for improved protein folding in a
Gaucher’s disease model (Ong et al., 2010). Additionally, these
(H) Glucose clearance is improved by bromocriptine.
(I) The area under the curve analysis of the glucose clearance in (C).
(J) Weight change per week identifies a significant decline after the 1st week of bromocriptine injections compared to vehicle or analog 688.
(K) Food intake significantly increased following bromocriptine administration during the 2nd and 3rd weeks of injection.
Data are mean ± SD. Statistical differences are based on one-way ANOVA followed by Tukey post hoc multiple comparisons test; *p < 0.05 versus vehicle (F and
G); **p < 0.01 bromocriptine versus vehicle (I); ***p < 0.001 bromocriptine versus vehicle and analog 688 at 1 week post-injection (J); two-way ANOVA; Dunnett’s
post hoc test; **p < 0.01 bromocriptine versus vehicle (H and K) weeks 1–3 drug treatment period. See also Figure S7.




compounds improve outcomes in models of diabetes and
ischemia, which may be due to effects on ER calcium and ER
proteostasis (Fansa et al., 2009; Maniskas et al., 2016; Ouardouz
et al., 2003; Ovalle et al., 2018).
Of the compounds identified in this study, bromocriptine
showed the most compelling activity across the panel of assays,
including protective effects in models of skeletal muscle calcium
dysregulation, Wolfram syndrome, oxygen-glucose deprivation,
T2D, and stroke.Bromocriptinewaspreviously reported toprotect
hippocampal neurons from ischemic insult in gerbils (Liu et al.,
1995) andwas similarly reported to improve ischemia and reperfu-
sion injury inheart (Gaoetal., 2013) andkidney (Narkaretal., 2004).
Ergot alkaloids, such as bromocriptine, have been postulated to
causemyocardial infarctionandstrokewhenusedclinically (Larra-
zet et al., 1993); however, this view is controversial, as subsequent
studies have found no association with ischemic injury (Arbouw
et al., 2012). In fact, a study of approximately 2,000 individuals tak-
ing bromocriptine for T2D revealed a 40% reduction in composite
cardiovascular events (Gaziano et al., 2010) and bromocriptine
improved peripartum cardiomyopathy (Hilfiker-Kleiner et al.,
2017). Currently, the mechanistic underpinnings of bromocrip-
tine’s cardioprotective effects are not known, but in light of the
findings presented herein, ER calcium homeostasis and ER pro-
teostasis may be positively affected.
The anti-exodosis activity of bromocriptine was consistently
observed across the disease models we tested. Over 50 years
ago, bromocriptine was discovered as an inhibitor of prolactin
secretion (Fl€uckiger andWagner, 1968), which later led to its clin-
ical use for hyperprolactinemia to treat acromegaly by reducing
circulating growth hormone levels (Lutterbeck et al., 1971;
Thorner et al., 1975). Subsequent work suggested dopamine in-
hibits prolactin secretion (MacLeod and Lehmeyer, 1974) and
bromocriptine-like molecules stimulate dopamine activity (Cor-
rodi et al., 1973). The effects of bromocriptine as a dopamine
agonist led to exploratory use in Parkinson’s disease patients,
where it showed beneficial effects (Calne et al., 1974). Once
the dopamine receptors had been identified, bromocriptine
was shown to bind the D2 dopamine receptor but also bind other
receptors, such as adrenergic and serotonergic receptors (Jäh-
nichen et al., 2005; Millan et al., 2002; Newman-Tancredi et al.,
2002). The ability of bromocriptine to signal through
non-dopaminergic receptors was confirmed in the current study
using a GPCR screen performed by the Psychoactive Drug
Screening Program (PDSP) (UNC Chapel Hill; Figure S6).
Historically, many of bromocriptine’s effects are ascribed to its
dopamine-related activity; however, its ability to alter other
GPCR-mediated signaling supports additional non-dopami-
nergic mechanisms of action. Throughout the many pre-clinical
and clinical applications of bromocriptine over the past 50 years,
the physiological changes have been viewed through the lens of
dopamine receptor modulation, and alterations in ER calcium
homeostasis have not received substantive investigation. A
notable exception is a study that identified bromocriptine as cy-
toprotective in a thapsigargin-induced model of cell death. The
bromocriptine-mediated protection was observed in cell lines
that lacked the D2R, leading the authors to speculate the mech-
anism was unrelated to its canonical D2 receptor activity (Kim
et al., 2012). In line with this interpretation, we found that bromo-
criptine, but not other D2 receptor agonists, could alter
SERCaMP secretion. Furthermore, the bromocriptine analogs
we designed, by functionalizing at the indole nitrogen of the
lysergic acid portion, had reduced D2R activity (2 to 3 orders
of magnitude) but demonstrated equipotent SERCaMP activity
and were equally or more efficacious in the stroke models. The
analog modifications are expected to disrupt the interaction
within a deep pocket surrounded by transmembrane domain
(TM)3, TM5, and TM6 of D2R, based on a recent cryo-electron
microscopy structure of bromocriptine bound to the lipid-mem-
brane-embedded receptor (Yin et al., 2020). We tested mole-
cules containing only the lysergic acid half of bromocriptine in
the SERCaMP assay and found they had no effect (Figure S8C),
further supporting that the ER-calcium-stabilizing effects are
mediated through the tripeptide portion of bromocriptine. It re-
mains possible that a non-dopamine receptor type GPCR medi-
ates the SERCaMP effect; however, we hypothesize that the ER-
calcium- and ER-proteome-stabilizing activity of bromocriptine
is mediated by a distinct target that has not yet been identified,
and our attempts to identify the target(s) have been unsuccessful
to date. Importantly, the development of bromocriptine analogs
represents an opportunity to evaluate therapeutic effects of
bromocriptine without unwanted side effects arising from its ac-
tivity on dopamine receptors and other GPCRs.
Bromocriptine’s action on hormone release led to its clinical use
for T2D (Pijl et al., 2000). Using a diet-induced obesity mouse
model of diabetes, we found that bromocriptine and analog 688
reduced fasting insulin and insulin resistance index HOMA-IR
compared to vehicle-treated animals, suggesting that bromocrip-
tine-induced improvement of fasting glucose metabolism was in-
dependent of D2R activation. In contrast, only bromocriptine
significantly improved the glucose tolerance test, suggesting
that bromocriptine was more effective than analog 688 at
reducing hyperglycemia due to its dopaminergic activity. Of
note, a transient drop in animal weight during the 1st week of
drug administration and an increase in food intake during the
2nd and 3rd weeks were observed only in the bromocriptine-
treated animals, which we hypothesize may be mediated by
dopamine-receptor activity. It has been postulated that
bromocriptine affects glucose homeostasis via prolactin, the mel-
anocortin system, and/or circadian rhythms related to its dopami-
nergic activity; however, a recent study demonstrated that the
disruption of these three systems has no impact on
bromocriptine’s effects in treating diabetes in mice (Framnes-De-
Boer et al., 2020). Our findings support a model in which bromo-
criptine modulates the ER stress response by altering the ER cal-
cium store, and our observations for analog 688 raise the
possibility that the beneficial effects of the T2D drug Cycloset
(quick-release bromocriptine mesylate) may be, in part, due to
its effects on ER calcium and exodosis. There is substantial evi-
dence that pancreatic beta cells and hepatocytes demonstrate
ER calcium dysregulation in models of diabetes and obesity
(Kang et al., 2016; Park et al., 2010; Santulli et al., 2015; Zhang
et al., 2020), suggesting this hypothesis warrants further attention.
Stabilization of ERcalciumhas been shown to reduce exodosis;
however, three of the five compounds tested in theGCaMPer fluo-
rescence assay did not acutely prevent a decrease in ER calcium
caused by thapsigargin treatment. These compounds may




function by augmenting activity of the KDEL receptor retrieval
pathway, which returns ERS-containing proteins from Golgi to
the ER (Munro and Pelham, 1987; Semenza et al., 1990). Notably,
the reversal of ER exodosis via stabilizing ER calcium and aug-
mentingKDELRretrievalwouldbeexpected tohavesimilar conse-
quences in cells and tissues. For example, ERS protein functions
would be preserved within the ER lumen (e.g., protein folding
and protein modification). Additionally, ERS proteins would not
be released into the extracellular space, where the gain of function
may have deleterious effects. Defining the consequences of exo-
dosis in disease settings is an area of ongoing research that will
benefit from the drugs identified in this study. In summary, our
study identifies a collection of small molecules (Table S1) that
can prevent the loss of ER resident proteins and may have thera-
peutic utility in diseases associated with ER calcium dysfunction.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
rabbit anti-BiP Cell Signaling Cat#3177S; RRID:AB_2119845
mouse anti-actin Abcam Cat#ab8226; RRID:AB 306371
mouse anti-PDI [RL90] Abcam Cat#2792; RRID:AB_303304
goat anti-rabbit IR800 Rockland Cat#611-132-122; RRID:AB_220152
goat anti-mouse IR700 Rockland Cat#610-130-121; RRID:AB_220121
Bacterial and virus strains
AAV-GLuc-SERCaMP Henderson et al., 2014 N/A
Biological samples
TTC stained Sprague dawley brain sections This paper N/A
C57BL/6J tail vein blood samples This paper N/A
CD-1 blood samples This paper N/A
Chemicals, peptides, and recombinant proteins
Dulbecco’s Modified Eagle Medium (1X) + GlutaMAX-I Thermo Fisher Scientific Cat#10569-010
Dulbecco’s Modified Eagle Medium (1X), no glucose Thermo Fisher Scientific Cat#11966-025
Opti-MEM Reduced Serum medium Thermo Fisher Scientific Cat#31985070
Bovine growth serum (BGS) GE Life Sciences / Hyclone Cat#SH30541.03
Fetal bovine serum (FBS) Millipore Sigma Cat#F6178
Horse serum Thermo Cat#16050130
Insulin, human Millipore Sigma Cat#I9278
Fibroblast growth factor, human Peprotech Cat#100-18B
Applied Cell Extracellular matrix Abmgood Cat#G422
Penicillin/streptomycin Thermo Fisher Scientific Cat#15140-122
2-mercaptoethanol Sigma Cat#M6250
RPMI-1640 Thermo Fisher Scientific Cat#61870036
Bovine serum albumin Sigma Cat#A9647
Thapsigargin Sigma Cat#T9033-1MG
Dantrolene Sigma Cat# D9175-250MG
Bromocriptine (in vitro) Sigma and Tocris Cat#B2134, Cat#2260-51-1




Brefeldin A Sigma Cat#B7651-5mg
Doxycycline Sigma Cat#D9891-1G
Blocking buffer Rockland Cat#MB-070
Tris-HCl pH 7.4 Quality Biological Cat#351-006-101
Sodium deoxycholate Millipore Sigma Cat#6750
EDTA Millipore Sigma Cat#E7889
NP-40 Thermo Fisher Scientific Cat#PI-28324
Tween-20 Bio-Rad Cat#1610781EDU
Protease inhibitors Millipore Sigma Cat#P8340-5ML
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
4-12% NuPAGE gels Thermo Fisher Scientific Cat#NP0329BOX
NuPAGE MOPS SDS running buffer Thermo Fisher Scientific Cat#NP0001
PDVF membranes, 0.2 mm Thermo Fisher Scientific Cat#LC2002
NuPAGE transfer buffer Thermo Fisher Scientific Cat#NP0006-1
Coelenterazine Regis Technologies Cat#1-361204.200
Furimazine Promega Cat#N1120
NuPAGE LDS sample buffer (4x) Thermo Fisher Scientific Cat#NP0007
fluorescein di-(1-methylcyclopropanecarboxymethyl ether Trychta et al., 2018b N/A
Chloral hydrate Sigma Cat#C8383
Triphenyltetrazolium chloride Sigma Cat#T8877
Paraformaldehyde Electron Microscopy Sciences Cat#19210
Critical commercial assays
CaspaseGlo 3/7 assay Promega Cat#G8091
DC Protein Assay Kit Bio-Rad Cat#5000112
MANF HTRF Cisbio Cat#63ADK056PEG
CellTiter-Glo Luminescent Cell Viability Assay (ATP assay) Promega Cat#G7571
Insulin ELISA Crystal Chem Inc Cat#90010
Mouse Insulin Standard Crystal Chem Inc Cat#90020
Free-fatty acid assay Fujifilm Wako Diagnostics 276-76491, 999-34691, 995-34791,
991-34891, 993-35191
Triglycerides assay Pointe Scientific Cat#23-666-410
Total cholesterol assay Thermo Scientific Cat#TR13421
Deposited data
Protocol Name: Primary qHTS for small molecule stabilizers
of the endoplasmic reticulum resident proteome: secreted
ER Calcium Modulated Protein (SERCaMP) assay
Pubchem AID 1508630
Protocol Name: Confirmatory qHTS for small molecule
stabilizers of the endoplasmic reticulum resident proteome:
secreted ER Calcium Modulated Protein (SERCaMP) assay
Pubchem AID 1508628
Protocol Name: Cell Viability qHTS for small molecule
stabilizers of the endoplasmic reticulum resident proteome
Pubchem AID 1508629
Protocol Name: Counterscreen qHTS for small molecule
stabilizers of the endoplasmic reticulum resident proteome:
GLuc-NoTag assay
Pubchem AID 1508627
Experimental models: cell lines




SH-SY5Y-GLuc-SERCaMP Henderson et al., 2014 SERCaMP reporter cell line
SH-SY5Y-GLuc Henderson et al., 2014 Control cell line
HEK293T ATCC ATCC CRL-3216
INS-1 832/13 pTetR TO shWfs1 Abreu et al., 2020 Cell Line 832/13 with inducible
Wfs1 knockdown
CHO-K1 (DRD2:bArrestin reporter) DiscoverX Cat#93-0579
Human skeletal muscle cells Dr. Katy Meilleur and
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental models: organisms/strains
Sprague -Dawley, WT Charles River Laboratories Strain Code: 400
C56Bl/6J Jackson Laboratories Stock: 000664
CD-1 Charles River Laboratories Strain Code: 022
Oligonucleotides
See Table S6 for oligonucleotide sequences nucleotide
sequences for all primers and probes (also described in
Trychta et al., 2018a)
Recombinant DNA
pAAV-EF1a-GCaMPer-10.19 Henderson et al., 2015a Addgene #63885
pAAV-5xUPRE-secNanoLuc Wires et al., 2017 Addgene #82497
pAAV-minimal promoter(cfos)-secNanoLuc Wires et al., 2017 Addgene #82498
pLenti6.3-CMV-SERCaMP (Tails Library) Trychta et al., 2018a N/A
D1R-Rluc Gs-mVenus Bonifazi et al., 2019 N/A
D2R-Rluc Gi1-mVenus Bonifazi et al., 2019 N/A
D3R-Rluc Gi1-mVenus Bonifazi et al., 2019 N/A
D4R-Rluc Gi1-mVenus Bonifazi et al., 2019 N/A
D5R-Rluc Gs-mVenus Bonifazi et al., 2019 N/A
Software and algorithms
GraphPad Prism 7 GraphPad https://www.graphpad.com/
scientific-software/prism/
Odyssey Infrared Imaging System 3.0.30 LI-COR Biosciences https://www.licor.com/bio/odyssey-clx/
qHTS data and curve fitting NCATS http://tripod.nih.gov/curvefit
Image Tool software University of Texas
Health Sciences Center
N/A
MassLynx V4.1 Waters N/A
Phoenix WinNonlin V6.2 Certara N/A
Other
1536-well tissue culture treated white microplates Corning Cat #7464
96-well tissue culture treated plates Fisher Scientific Cat#08-772-2C
12-well tissue culture treated plates Fisher Scientific Cat#08-772-29
384-well black walled plates (esterase assay) PerkinElmer Cat#6057300
High-fat chow, 60% fat Research Diets Cat#D12492
ViewLux high-throughput imaging system PerkinElmer PerkinElmer 1430
Biotek Synergy II microplate reader Biotek https://www.biotek.com
Biotek Syndergy H1 microplate reader Biotek https://www.biotek.com
Pherastar FSX BMG Labtech N/A
Breathe Easy microplate sealing film Diversified Biotech,
via Sigma
Cat#Z380059
NucleoSpin RNA kit Takara Cat#740955
iScript cDNA synthesis kit Bio-Rad Cat#1708891
Taqman Universal PCR Master Mix Thermo Fisher Scientific Cat#4305719
Lipofectamine 2000 Transfection Reagent Thermo Fisher Scientific Cat#11668019
Protein A SureBeads BioRad Cat#1614013
X-fect Takara Cat#631318
Acquity BEH C18 column Waters Cat#186002350
C1000 Thermal Cycler CFX96 Real-Time System Bio-Rad Cat#1855195
Hypoxia chambers Billups-Rothenberg Cat#MIC-101






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Brandon
Harvey (BHarvey@intra.nida.nih.gov).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The datasets reported in this paper are available at Pubchem (AID numbers 1508627-1508630).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal studies
MCAO stroke model
Adult male Sprague-Dawley rats (8-12 weeks, weight 250-300 g; n = 6-11 per treatment group) surgeries were done in accordance
with the animal care guidelines of the ‘‘Principles of Laboratory Care’’ (National Institutes of Health publication No. 86-23, 1996) and
were approved by the National Health Research Institutes (Taiwan) Animal Care and Use Committee (Protocol No. 105079-A;
105080).
Diet induced obesity model
C57BL/6J male mice (15 weeks) were obtained from Jackson Laboratories (Bar Harbor, ME). Animals were assigned to treatment
groups (n = 10 per group, mean starting weight was 40 g in each group). All animal studies related to high fat diet were carried
out according to the US National Institutes of Health Guidelines for Animal Research and were approved by the NIDDK Institutional
Animal Care and Use Committee. We complied with all relevant ethical regulations for animal testing and research.
Pharmacokinetics
AdultmaleCD-1mice (8weeks, n = 3/sampling timepoint) were purchased fromCharlesRiver Laboratories (Wilmington,MA). All exper-
imental procedures were approved by the Animal Care and Use Committee (ACUC) of the NIH Division of Veterinary Resources (DVR).
Cell Lines
SH-SY5Y
Human neuroblastoma cells (ATCC CRL-2266) were maintained in Dulbecco’s Modified Eagle Medium (DMEM + GlutaMAX, 4.5 g/L
D-glucose, 110 mg/L sodium pyruvate; Thermo Fisher Scientific, Waltham, MA) supplemented with 10 units/mL penicillin, 10 mg/mL
streptomycin (Thermo Fisher Scientific), and 10%bovine growth serum (BGS; GE Life Sciences). Cells were grown at 37Cwith 5.5%
CO2 in a humidified incubator. Cell lines stably expressing Gaussia luciferase SERCaMP reporter variants were generated by lentiviral
transduction as previously described (Henderson et al., 2014).
HEK293T
Embryonic kidney cells (ATCC CRL-3216) were maintained in Dulbecco’s Modified Eagle Medium (DMEM, 4.5 g/L D-glucose, Glu-
tamax, 110 mg/L sodium pyruvate; Thermo Fisher Scientific, Waltham, MA) supplemented with 10 units/mL penicillin, 10 mg/mL
streptomycin (Thermo Fisher Scientific).
INS-1 832/13
Rat insulinoma cell line INS-1 832/13 pTetR TO shWfs1 cells were generated as previously described (Abreu et al., 2020). Cells were
cultured in RPMI-1640 medium (Thermo #11875) supplemented with 10% tetracycline screened fetal bovine serum (Hyclone
SH30070.03), 1 mM sodium pyruvate, 10 U/ml penicillin (GIBCO), 10 mg/ml streptomycin (GIBCO), and b-mercaptoethanol (1:200,000).
CHO-K1 (DRD2:bArrestin reporter)
Chinese hamster ovary cells (expressing DRD2 long isoform tagged with ProLink and b-Arrestin tagged with Enzyme acceptor) were
obtained from DiscoverX (catalog 93-0579). Frozen cells were seeded to assay plates as described below.
Human Skeletal Muscle Cells
Primary humanmyoblasts (obtained through the National Disease Research Interchange and provided by Drs. Joshua Todd andKaty
Meilleur, National Institute of Nursing Research) were cultured in a 37C humidified incubator with 5.5% CO2 with in DMEM (4.5 g/L
D-glucose; Thermo Fisher), 20% FBS (Sigma), 1% penicillin-streptomycin (ThermoFisher Scientific), 5 mg/ml human insulin (Sigma),
25 ng/ml human fibroblast growth factor (Peprotech) on dishes pre-coated with extracellular matrix (ABMGood, #G422).
METHOD DETAILS
qHTS primary screen (SERCaMP) and counterscreens
SH-SY5Y human neuroblastoma cells stably expressing GLuc-SERCaMP (SH-SY5Y-GLuc-SERCaMP) cells were seeded at 1,000
cells per well (5 mL volume) in 1,536 well white tissue culture treated plates (Corning, Cat #7464) in DMEM-high glucose-sodium




pyruvate (ThermoFisher Scientific, Cat #10569) supplemented with 10% bovine growth serum (Hyclone), 10 U/ml penicillin (GIBCO),
10 mg/ml streptomycin (GIBCO), and 20 mM HEPES. Cells were incubated for 5 h at 37C in a humidified incubator containing 5%
CO2. qHTS libraries (23 nl, final concentrations of 1.53 mM, 7.67 mM, 38.3 mM) or controls (neutral control: DMSO, positive control:
dantrolene) were added using a Kalypsis pin-tool. Cells were incubated for 16 h (37C, 5% CO2) and thapsigargin was added at
100 nM to deplete ER calcium stores. Cells were incubated for 4 h (37C, 5% CO2) and Gaussia luciferase in the medium was
measured by adding 1 mL of 0.5x coelenterazine (final concentration 0.07x) prepared in Gaussia Luciferase Glow Assay Buffer
(Pierce), without addition of the Cell Lysis Buffer Reagent. Luminescence was measured using a ViewLux high-throughput CCD im-
aging system (Perkin Elmer) equipped with clear filters. Compounds exhibiting inhibitory activity (defined as curve class 1.1, 1.2,
1.3,1.4,2.1,2.2,2.3,2.4,3) were identified by normalizing plate-wise to corresponding intra-plate controls (neutral con-
trol = Tg only; positive control (100% inhibition) = DMSO vehicle) with percent activity derived using in-house software (http://tripod.
nih.gov/curvefit). The same controls were also used for the calculation of the Z’ factor, a measure of assay quality control, as previ-
ously described (Zhang et al., 1999). For the initial validation of activity in the SERCaMP assays, hits from the primary screen were
assayed again at 11-concentrations (1.3 nM – 76.6 mM). SH-SY5Y-GLuc-SERCaMP cells were assayed for ER Ca2+ depletion as out-
lined above. All screening results are publicly available at PubChem AID 1508627, 1508628, 1508629, 1508630.
SERCaMP assay (96 well format)
SH-SY5Y-GLuc-SERCaMP cells were cultured in a 37C humidified incubator with 5.5%CO2 in DMEM (4.5 g/L D-glucose, 110mg/L
sodium pyruvate) containing 2 mM GlutaMAX, 10% bovine growth serum (Hyclone), 10 U/ml penicillin (GIBCO), and 10 mg/ml strep-
tomycin (GIBCO). Cells were plated at 5 3 104 cells per well (100 ml volume), returned to the incubator for 5 h for attachment, and
treated with compounds (or DMSO control). Compound-treated cells were incubated for 16 h (standard SERCaMP screening assay)
or 0.5 h (acute ER Ca2+ protocol) prior to adding 100 nM thapsigargin (Sigma). After thapsigargin treatment, 5 ml of medium was
collected for enzymatic assay as previously described (Henderson et al., 2015b). Briefly, 5 ml medium was transferred to an opaque
walled plate, 100 ml of 8 mM coelenterazine (diluted in 1x PBS) was injected using a BioTek Synergy II Plate reader equipped with
injection, and luminescence was measured. For the testing drug efficacy relative to timing of Tg (30 min pre-Tg to 4 h post-Tg)
SH-SY5Y-GLuc-SERCaMP cells were plated and incubated for 48 h before being treated with 200 nM thapsigargin. All drugs
were given at indicated time relative to Tg at 30 mM final concentration. 5 mL of cell culture media was collected immediately before
adding thapsigargin as well as 8 h after thapsigargin addition and assayed as described above.
Oxygen-glucose deprivation (OGD)
SH-SY5Y-Gluc-SERCaMP were seeded at 53 104 cells per well in 96 well plates (100 ml volume). Cells were maintained in a humid-
ified incubator at 37Cwith 5.5%CO2 in DMEM (4.5 g/L D-glucose) + 110mg/L sodium pyruvate + 10% fetal bovine serum + 10 U/ml
penicillin, + 10 mg/ml streptomycin. Cells were incubated for 24 h before beginning the OGD procedure. For plates subjected to OGD,
DMEM (10% FBS; without Glucose) was deoxygenated by bubbling a gas mixture containing 5% CO2, 10% H2, 85% N2 air mixture
through a glass filter stick (ACE glass, Vineland NJ) for 15 minutes. Compounds were added to the deoxygenated media and imme-
diately added to the plate by complete media exchange. The plates were placed into hypoxia chamber (Billups-Rothenberg, Modular
Incubator Chamber) and the air inside the chamber was replaced with a 5%CO2, 10%H2, 85%N2 air mixture to remove oxygen. The
hypoxia chamber was returned to the 37C incubator. After 16 h of oxygen-glucose deprivation, the deoxygenated medium was
exchanged with complete growth media and plates were returned to normoxic incubator conditions (reperfusion). Cell viability
was measured 24 h post-normoxia using a CellTiter-Glo assay kit (Promega), as outlined below. GLuc-SERCaMP activity was
measured in medium collected from the cells, as described above. For normoxia control plates, all medium exchanges occurred
concurrently with OGD samples, using standard culture medium and returning the cells to oxygen-containing incubators (ambient
air, 5% CO2). For endogenous SERCaMP (esterase) experiments, the reperfusion media exchange consisted of a full media ex-
change into esterase assay medium (150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 20 mM HEPES, 1 mM CaCl2, and 1.9 g/L glucose)
and media was collected 8 h after reperfusion.
Cell viability/ATP assay
Cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Briefly, an equal volume of reagent
was added to each well. Plates were rotated for 2 min and incubated for 10 min at room temperature. 100 ml of the solution was
transferred from clear walled tissue culture plates to opaque walled assay plates, and luminescence was measured using a BioTek
Synergy II plate reader (Winooski, VT).
Immunoblots
SH-SY5Y-SERCaMP cells were plated at 7.5 3 105 cells per well (1.5 mL volume) in 12-well plates, returned to incubator for 6 h to
adhere, incubated with compounds overnight, and treated with thapsigargin (or vehicle control) for 4 h. Cells were rinsed in PBS and
lysed in a modified RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 150 mMNaCl, 1 mM EDTA, 1% Nonidet P-40, and 13 protease
inhibitors (Sigma). Plates were rotated for at least 20 minutes at 4C. Lysates were centrifuged for 10 min at 13,000 x g (4C) and
quantified using a DC assay (Bio-Rad). Equal amounts of total protein were loaded on 4%–12% NuPAGE gels with MOPS running
buffer (ThermoFisher, WalthamMA). Proteins were transferred to 0.20 mmpolyvinylidene fluoridemembranes (Life Technologies) and




immunoblotted with the primary antibodies diluted in LI-COR blocking reagent (LI-COR Biosciences, Lincoln, NE). Secondary
antibodies were IR700 and IR800 (Rockland Immunochemicals, Gilbertsville, PA), and blots were scanned using anOdyssey scanner
(LI-COR).
GCaMPer assay
SH-SY5Y cells were seeded in 25 cm2 flasks at 43 105 cells per ml (5 mL volume) and allowed to adhere overnight. Cells were trans-
fected with pAAV-EF1a-GCaMPer-10.19 (Addgene #63885) (Henderson et al., 2015a), using 6 mg plasmid DNA and 10 ml of Lipofect-
amine 2000. After 48 h, cells were detached using trypsin and re-seeded in 96 well plates at 53 104 cells per well (100 ml volume) in
DMEM (4.5 g/L D-glucose, 110mg/L sodium pyruvate) + 2mMGlutaMAX, 10%bovine growth serum, 10 U/ml penicillin, and 10 mg/ml
streptomycin. After overnight incubation, cells were rinsed with 150 ml imaging medium (150 mM NaCl, 20 mM HEPES, 5 mM KCl,
1 mMMgCl2, 1 mM CaCl2, 1.9 g/L D-glucose, 1.9 g/L bovine serum albumin, pH 7.4). 90 ml of fresh imaging medium was added and
cells were allowed to equilibrate for 1 h at room temperature. Pre-treatment images were captured on a Nikon EclipseTE2000-E in-
verted microscope equipped with a Nikon 20x (0.45 NA) Plan Fluor objective and an Andor iXon3 high sensitivity EMCCD camera
(Andor Technology, Belfast, UK). Multi-point x-y-z coordinates were set using a Prior Proscan III motorized stage (Prior Scientific,
Rockland, MA). To account for Z-drift, images were captured in five Z-planes (10 micron below initial plane to 10 microns above)
with the Elements AR software used to determine the in-focus plane for collection. For fluorescence quantitation, individual
cells were selected using ImageJ software. Background-subtracted fluorescence intensity was measured at each time point
(to derive Ft). Relative fluorescence (Ft/F0) was calculated as a ratio relative to fluorescence at time point zero.
UPRE luciferase reporter assay
SH-SY5Y cells were plated in 25 cm2 flasks at 1.75 3 105 cells (5 mL volume) and incubated overnight. Cells were transfected with
5 mg of pAAV-5xUPRE-secNanoLuc or pAAV-minimal promoter(cfos)-secNanoLuc (Wires et al., 2017) and 10 ml lipofectamine 2000
diluted in Opti-MEM Reduced Serum Media (ThermoFisher). After 3 h of incubation, the transfection media was replaced with 5 mL
complete cell culturemedia and cells were incubated for 48 h. Cells were then trypsinized, counted, and re-plated to 96-well plates at
5.0x104 cells per well (100 mL volume). After allowing to adhere for 4 h cells were treated with compound and incubated at 37C
overnight. Cells were then treated with 100 nM thapsigargin (or vehicle control) and returned to the incubator for 16 h. 5 mL of culture
medium was transferred to an opaque 96-well plate and 100 uL of furimazine (Promega) substrate (prepared according to the
manufacturer’s protocol and then diluted 20-fold in 1x PBS) was injected to each well and luminescence recorded using a BioTek
Synergy II plate reader (BioTek).
ER stress response transcriptional analysis
Total RNA was isolated from cells maintained on 24-well (plating density 2.5x105 SH-SY5Y cells/500ml) or 12-well (plating density
5 3 105 INS-1 832/13 cells/2 ml) plates using NucleoSpin RNA kit (Takara), including an on-column DNA digest treatment. RNA
(0.5 mg) was reversed transcribed using iScript cDNA synthesis kit (Bio-Rad), and diluted 1:20 with nuclease-free water. 5 ml of
cDNA were applied onto 96-well opaque PCR plates (Bio-Rad) together with TaqMan Universal PCR Master Mix (Thermo Fisher),
450 nM primers and 100 nM probe to a final reaction volume of 20 ml. Real time qPCR was performed with C1000 Thermal Cycler
CFX96 Real-Time System (Bio-Rad) using following template: pre-incubation approximately 9 min (50C for 10 s followed by photo-
bleach, repeat 20x, 95C for 5min), and amplification with 50 repeats (94C for 20 s, 60C for 1min). Results were quantified using the
Bio-Rad CFX Manager software with Cq values determined using the single threshold mode. All Cq values were normalized to the
geometric mean of the Cq for the reference genes ubiquitin-conjugating enzyme 2i (Ube2i) and RNA polymerase II (PRNAII) (delta
Cq), and results are presented as the 2-ddCq value ± upper and lower limits (limits calculated based on the standard deviation of delta
Cq values). Following sequences were used for target amplification and detection: human ASNS, ggattggctgccttttatcagg (forward),
ggcttctttcagctgcttcaac (reverse), tggactccagcttggttgctgcc (FAM-labeled probe); human BiP, gttgtggccactaatggagatac (forward),
ggagtttctgcacagctctattg (reverse), acgctggtcaaagtcttctccaccca (FAM-labeled probe); human ERdj4, gccatgaagtaccaccctg
(forward), ccactagtaaaagcactgtgtc (reverse), ctgcaatctctctgaattttgcttcagc (FAM-labeled probe); human PRNAII, gcaccacgtccaatga
cattg (forward), ggagccatcaaaggagatgac (reverse), acggcttcaatgcccagcaccg (HEX-labeled probe); human Ube2i, gtgtgcctgtccatct
tagag (forward), gctgggtcttggatatttggttc (reverse), caaggactggaggccagccatcac (HEX-labeled probe); rat ASNS, ggattggctgccttttat
cagg (forward), ctccttgagttgcttcagcag (reverse), tggactccagcttggttgctgcc (FAM-labeled probe); rat BiP, agtggtggccactaatggagac
(forward), ggagtttctgcacagctctgttg (reverse), cccgctgatcaaagtcttccccacccag (FAM-labeled probe); rat ERdj4, gccatgaagtaccaccctg
(forward), ccattagtaaaagcactgtgtcc (reverse), ctgcaatctctctgaattttgcttcagc (FAM-labeled probe); rat PRNAII, tagtcctacctactccc
caacttc (forward), agtagccaggagaagtgggag (reverse), actcgcccaccagtcccacctact (HEX-labeled probe); rat Ube2i, gccaccactgttt
catccaaa (forward), gccgccagtccttgtcttc (reverse), cgtgtatccttctggcacagtgtgc (HEX-labeled probe) (Integrated DNA Technologies,
Coralville, IA).
SERCaMP library
A SERCaMP library was created by fusing the last seven amino acids from human proteins to the C terminus of GLuc with a MANF
N-terminal signal peptide as previously described (Trychta et al., 2018a). Inclusion criteria followed those set out by Raykhel et al.
(2007) in which only soluble proteins with a signal peptide and a putative ER retention motif defined as XX[DE][FLM] were considered.




Customoligonucleotides coding for each seven amino acid carboxy-terminal tail (synthesized by Integrated DNA Technologies) were
annealed to form a duplex and then inserted into a pLenti6.3-CMV-MANF sigpep-GLuc-MCS plasmid using Ligate-IT (Affymetrix)
according to the manufacturer’s protocol. The ER retention motifs used in this paper are detailed in Table S2.
Expression of GLuc-SERCaMPs in SH-SY5Y was achieved via reverse transfection using X-fect (Clontech). Briefly, transfection
complexes containing 200 ng of plasmid DNA and 0.06 mL of X-fect in a final volume of 10 mL were added to opaque TC-treated
96-well plates. 5 3 104 cells in 90 mL of antibiotic-free cell culture media were plated on top of the transfection complexes. In the
OGD paradigm, cells were incubated for 48 h before beginning the OGD procedure as described above. At the conclusion of the
experiment, both cell culturemedia and cell lysates were collected and assayed for GLuc. 5 mL ofmedia was collected into an opaque
walled plate and assayed as described above. Cell lysates were collected following the complete removal of cell culture media and a
rinse with 1x PBS (GIBCO) at which point 75 mL of lysis buffer (50mMTris (pH 7.5), 150mMNaCl, 1%NP40, and 1x protease inhibitor
cocktail (Sigma)) was added to the well. Cells were lysed in and GLuc was assayed from the original culture plate. Secretion index
refers to the ratio of extracellular GLuc to intracellular GLuc.
Wolfram caspase 3/7 assay
INS-1 832/13 pTetR TO shWfs1 cells were seeded to 1536-well plates, allowed to adhere overnight then treated with 2 mg/mL doxy-
cycline (Clontech) or vehicle control. After 48 h, 5 mL of Caspase-Glo 3/7 reagent was added to each well, the plate was incubated at
room temperature for 30 min and luminescence was measured using a ViewLux microplate imager.
Human skeletal muscle exodosis assay
Primary human myoblasts were plated in 96 well plates pre-coated with 3 mg/ml Matrigel (Corning) at 7.3x103cells/well. One day
post-plating, myoblasts were differentiated in DMEM (4.5 g/L D-glucose), 5% horse serum (Thermo Fisher), 1% penicillin-strepto-
mycin, and 5mg/mL human insulin for 72 h. Myotubes were transduced with AAV-GLuc-SERCaMP (1.45x108 vg/well) in growth
media. 48 h post-transduction myotubes were pre-treated with bromocriptine, dantrolene, dextromethorphan, verapamil, diltiazem
or vehicle for 30 mins prior to the addition of 100nM of thapsigargin. Media was collected 4-8 h post-thapsigargin.
Monitoring endogenous SERCaMPs (esterase, MANF and PDI)
SH-SY5Y cells were plated with 5 3 104 cells/well in a 96-well (esterase assay) or 6.3 3 105 cells/well in a 12-well plate (MANF and
PDI). A full media exchange into growth media containing 1.5% BGS was performed 28 h after plating. 200 nM of thapsigargin was
added 16 h after the full media exchange. Bromocriptine (20 mM) was added either 30 min prior to thapsigargin addition or 1 h after.
Bromocriptine/vehicle treatments were done as pre-treatments with bromocriptine being added 30 min prior to treatment with
vehicle. Cell culture media was collected 8 h after the addition of Tg. Collected media samples were centrifuged at 4C for 5 min
at 1000x g and stored at 80C until the time of use. Secreted Esterase assay: For esterase assays, at the time of drug treatment
a full media exchange was performed into esterase assay medium (150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 20 mM HEPES, 1 mM
CaCl2, and 1.9 g/L glucose). Esterase activity was measured by fluorescence generated from fluorescein di-(1-methylcyclopropane-
carboxymethyl ether) and quantified by BioTek Synergy H2 plate reader (Excitation 465 nm/Emission 528 nm) as previously
described (Trychta et al., 2018b). Briefly, 50 mL of cell culture medium was transferred to a black walled clear bottomed plate (Perkin
Elmer). 50 mL of 100 mM esterase substrate (pH 5) was added to each well and fluorescence was measured 1 h after substrate addi-
tion. For all esterase measurements cells were maintained in phenol red-free and serum-free media for 8 h prior to media collection.
Secreted MANF HTRF assay: The concentration of MANF in cell culture media samples was determined using a MANF HTRF assay
according to the manufacturer’s instructions (Cisbio). Briefly, media samples were diluted 1:2 in the provided dilution buffer. 16 mL of
media sample, 2 mL of anti-Human MANF-d2 antibody, and 2 mL of anti-Human-Eu3+ cryptate antibody were incubated together in a
white plate for 24 h before fluorescence wasmeasured at 665 nm and 620 nm. Sample readouts were compared to aMANF standard
curve to determine the amount of MANF in each sample. Secreted PDI assay:Magnetic Protein A beads (SureBeads, Bio-Rad) were
washed with PBS + 0.1% Tween (PBS-T) then incubated with PDI antibody (AbcamCat. ab2792) diluted 1:100 in PBS-T for 10 min at
room temperature. Beads were washed with PBS-T then incubated with 400 mL of media for 1 h at room temperature. Beads were
washed for a final time with PBS-T and then samples were eluted using 40 mL of 1x LDS (Thermo Fisher Scientific) and incubation at
70C for 10 min. Equal volumes of samples were run on 4%–12% Bis-Tris NuPage gels (Thermo Fisher Scientific) using MOPS
running buffer (Thermo Fisher Scientific). Proteins were transferred to 0.45 mm PVDF membranes (Thermo Fisher Scientific) and
immunoblotted with PDI antibody (Abcam Cat. ab2792). Blots were scanned using an Odyssey scanner.
In vivo distal middle cerebral artery occlusion (MCAO)
Animal surgeries were done in accordance with the animal care guidelines of the ‘‘Principles of Laboratory Care’’ (National Institutes
of Health publication No. 86-23, 1996) and were approved by the National Health Research Institutes (Taiwan) Animal Care and Use
Committee (Protocol No. 105079-A; 105080). Adult male Sprague-Dawley rats were subjected to right middle cerebral artery occlu-
sion (MCAo) as described previously (Airavaara et al., 2010). Animals were anesthetized with an intraperitoneal injection of chloral
hydrate (0.4 g/kg). Fifteen minutes prior to MCAo, rats were given 20 uL of vehicle, bromocriptine or bromocriptine analogs intracer-
ebroventricularly, contralateral to the ischemic hemisphere. The speed of the injection was 2.5 mL/min and was controlled by a
syringe pump. The needle was retained in place for 5 min following the injection. The right middle cerebral artery (MCA) was ligated




with a 10-0 suture, and bilateral common carotid arteries were ligated with arterial clamps for 60 min. After 60 min of ischemia, the
suture around the MCA and arterial clips were removed. After recovery from anesthesia, the rats were returned to their home cage.
Core body temperature was maintained at 37C throughout the procedure and during anesthesia recovery.
Triphenyltetrazolium chloride (TTC) staining
Two days after MCAO, animals were culled by decapitation. The brains were removed, immersed in cold saline for 5 min, and sliced
into 2.0 mm thick sections. The brain slices were incubated in 2% triphenyltetrazolium chloride (Sigma), dissolved in normal saline for
10 min at room temperature, and then transferred into a 5% formaldehyde solution for fixation. The area of infarction on each brain
slice was measured double blind using a digital scanner and the Image Tools program (University of Texas Health Sciences Center).
Behavioral Assay
Two days after MCAO body asymmetry was analyzed using an elevated body asymmetry test.(Borlongan et al., 1998) Rats were
examined for lateral movement/turning while their bodies were suspended by their tail 20 cm above the testing table. The frequency
of initial turning of the head or upper body contralateral to the ischemic side was counted in 20 consecutive trials. The maximum
impairment in body asymmetry is 20 contralateral turns in 20 trials. Normal body asymmetry is 10 contralateral turns in 20 trials
(animals turn in either direction with equal frequency).
Pharmacokinetics of bromocriptine, analog 686 and analog 688
Adult male CD-1 mice (n = 3/sampling time point) were purchased from Charles Reviver Laboratories (Wilmington, MA). All experi-
mental procedures were approved by the Animal Care andUseCommittee (ACUC) of the NIHDivision of Veterinary Resources (DVR).
A single dose of 2 mg/kg intravenous (IV) and 30 mg/kg intraperitoneal administration was conducted for all three compounds.
Dosing solutions were freshly prepared on the day of administration in 20% PEG300/H2O. The blood samples were collected in
K2EDTA tubes and plasma was harvested after centrifugation at 2200 3 g at 5
C for 10 min. Brain, liver and pancreas samples
were flash frozen in liquid nitrogen in pre-weighed vials and transferred to 48-well plates. All plasma and tissue samples were stored
at 80C until analysis.
Ultra-performance liquid chromatography-tandemmass spectrometry (UPLC-MS/MS)methodswere developed to determine test
compounds’ concentrations in mouse plasma and tissue samples. Mass spectrometric analysis was performed on a Waters Xevo
TQ-S triple quadrupole instrument using electrospray ionization in positive mode with the selected reaction monitoring. The separa-
tion of test compounds from endogenous components was performed on an Acquity BEH C18 column (503 2.1 mm, 1.7 m) using a
Waters Acquity UPLC system with 0.6 mL/min flow rate and gradient elution. The mobile phases were 0.1% formic acid in water and
0.1% formic acid in acetonitrile. The calibration standards and quality control samples were prepared in the blankmouse plasma and
tissue homogenate. Aliquots of 10 mL plasma samples or tissue homogenate were mixed with 200 mL internal standard in acetonitrile
to precipitate proteins in a 96-well plate. 0.1-1.0 mL supernatant was injected for the UPLC-MS/MS analysis of different biological
matrices. Data were analyzed using MassLynx V4.1 (Waters Corp., Milford, MA).
The pharmacokinetic (PK) parameters were calculated using the non-compartmental approach of the PK software Phoenix Win-
Nonlin, version 6.2 (Certara, St. Louis, MO). The area under the plasma concentration versus time curve (AUC) was calculated using
the linear trapezoidal method. The slope of the apparent terminal phase was estimated by log linear regression using at least 3 data
points and the terminal rate constant (k) was derived from the slope. AUC0-inf was estimated as the sum of the AUC0-t (where t is the
time of the last measurable concentration) and Ct/k. The apparent terminal half-life (t½) was calculated as 0.693/k. The plasma clear-
ance (CLp) and volume of distribution at steady-state (Vdss) was calculated after IV administration.
Metabolic testing in Diet Induced Obese (DIO) mice
C57BL/6J male mice were obtained from Jackson Laboratories (Bar Harbor, ME) and were fed high fat diet (D12492, 60% fat,
Research Diets Inc) for 8 weeks. Three weeks prior to the initiation of treatment mice were singly housed and randomized into 3
groups (10 mice/group): vehicle control (20% PEG300 in water), bromocriptine mesylate (BOS Sciences, Shirley, NY, CAS No.:
22260-51-1, 12 mg/kg), and bromocriptine analog 688 (NCATS, NCGC00537688-02, 12 mg/kg). Note that one mouse was excluded
from analog 688 group (n = 9) based on Grubbs’ outlier test in multiple endpoints. The dosing solutions were prepared fresh daily and
were administered intraperitoneally at the end of the light cycle (17:00). Body weight, body composition, and food intake were
measured weekly. Body composition was measured by time domain Echo MRI 3-in-1 (Echo Medical Systems, Houston, TX). Energy
expenditure was calculated from the metabolizable caloric intake, corrected for the change in caloric content of the mouse (from the
change in body composition over the measurement interval) (Ravussin et al., 2013). Blood samples were collected once a week from
the tail vein in randomly fed state for measuring blood glucose and serum parameters. Intraperitoneal glucose (1 g/kg, with AUC
calculated from 0 mg/dl) tolerance tests were performed at 09:00, following an overnight (16 h) fast. Glucose was measured with
a Glucometer Contour (Bayer, Mishawaka, IN). Insulin resistance index was calculated using homeostasis model assessment
HOMA-IR = [fasting insulin (mIU/L)*fasting glucose (mg/dl)]/405. Free fatty acids (FFA, Roche Diagnostics GmbH, Mannheim,
Germany), triglycerides (Pointe Scientific Inc., Canton,MI), and cholesterol (Thermo Scientific, Middletown, VA) weremeasured using
the indicated colorimetric assays. Insulin was measured by ELISA (Crystal Chem, Downers Grove, IL). Data presented are from
3 weeks of drug treatment. All animal studies related to high fat diet were carried out according to the US National Institutes of Health




Guidelines for Animal Research andwere approved by the NIDDK Institutional Animal Care and UseCommittee. We complied with all
relevant ethical regulations for animal testing and research.
Bromocriptine analogs chemistry
General Methods for Chemistry. All air or moisture sensitive reactions were performed under positive pressure of nitrogen with
oven-dried glassware. Chemical reagents and anhydrous solvents were obtained from commercial sources and used as-is.
Analytical analysis for purity was determined by two different methods denoted as Final QC Methods 1 and 2. Method 1:
Analysis was performed on an Agilent 1290 Infinity Series HPLC. UHPLC Long Gradient Equivalent 4% to 100% acetonitrile
(0.05% trifluoroacetic acid) in water over 3 minutes run time of 4.5 minutes with a flow rate of 0.8 mL/min. A Phenomenex Luna
C18 column (3 micron, 3 3 75 mm) was used at a temperature of 50C. Method 2: analysis was performed on an Agilent
1260 with a 7 minute gradient of 4% to 100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05%
trifluoroacetic acid) over 8 minute run time at a flow rate of 1 mL/min. A Phenomenex Luna C18 column (3 micron, 3 3 75 mm)
was used at a temperature of 50C. Purity determination was performed using an Agilent Diode Array Detector for both Method
1 and Method 2. Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray ionization in
the positive mode. All of the analogs for assay have purity greater than 95% based on both analytical methods. 1H NMR




HCl (analog 686). To a suspension of (6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxoocta-
hydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl 4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide, mesy-
late (0.75 g, 1.0 mmol) in CH2Cl2 (12 ml) was added Et3N (0.56 ml, 4.0 mmol) and then cyclopropanecarbonyl chloride (0.21 g,
2.0 mmol). The mixture was stirred at room temperature for 3 hr. To the mixture was added H2O (10 mL) and the aqueous layer
was extracted with CH2Cl2 (5 mL x 2). The combined organic layer was dried (Na2SO4) and filtered. After removal of solvent,
the product was purified by silica gel chromatography using 0-100 EtOAc/hexane as the eluent to give (6aR,9R)-5-bromo-4-(cyclo-
propanecarbonyl)-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]
pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (a free base of analog 686, 372 mg,
0.52 mmol, 51.5% yield; LC-MS (Method 1): tR = 3.10 min, m/z (M+H)
+ = 722 and 724). This material (372 mg, 0.52 mmol)
was then dissolved in 1,4-dioxane (6 ml) and HCl (4 M in 1,4-dioxane, 1.03 mmol, 257 ul, 2 equiv) was added. The mixture was
stirred at room temperature for 5 min and hexane (15 mL) was added. The solid was filtered, washed with hexane (5 mL x 2), and
then dried to give (6aR,9R)-5-bromo-4-(cyclopropanecarbonyl)-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-
dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxa-
mide, HCl (analog 686, 339 mg, 0.45 mmol, 87% yield) as a HCl salt. 1H NMR (400 MHz, DMSO-d6) d 11.65 (s, 1H), 9.58 (s, 1H),
7.83 (d, J = 8.2 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H), 7.16 (s, 1H), 6.45 (s, 1H), 4.40 (br s, 1H), 4.32 (t, J =
6.7 Hz, 1H), 4.21 (br s, 1H), 3.81–3.69 (m, 2H), 3.61 – 3.26 (m, 4H), 3.15 – 2.97 (m, 4H), 2.68 – 2.54 (m, 1H), 2.24 – 1.54 (m, 8H),
1.27 –1.21 (m, 4H), 1.05 (d, J = 6.7 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H), 0.89 (d, J = 6.7 Hz, 3H), 0.77 (d, J = 6.7 Hz, 3H); LC-MS (Method
2): tR = 4.89 min, m/z (M+H)
+ = 722 and 724; HRMS calculated for C36H45BrN5O6 (M+H)




(analog 688). To a suspension of (6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahy-
dro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide, Mesylate
(998 mg, 1.33 mmol) in CH2Cl2 (6 ml) was added Et3N (0.28 ml, 2.0 mmol) and then isocyanatocyclopropane (332 mg, 4.0 mmol). The
mixture was stirred at rt for 6 hr. The mixture was then concentrated and then purified by silica gel chromatography using 0-100
EtOAc/hexane as the eluent to give (6aR,9R)-5-bromo-N4-cyclopropyl-N9-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopro-
pyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-6a,7,8,9-tetrahydroindolo[4,3-fg]quinoline-4,9(6H)-
dicarboxamide (a free base of analog 688, 566 mg, 0.77 mmol, 57.7% yield; LC-MS (Method 1): tR = 2.88 min, m/z (M+H)
+ = 737 and
739). This material (566 mg, 0.767 mmol) was then dissolved in 1,4-dioxane (6 ml) and HCl (4 M in 1,4-dioxane, 2.3 mmol, 575 ul, 3
equiv) was added. Themixture was stirred at rt for 5min and hexane (15mL) was added slowly. The solid was stirred for another 5min
and filtered. The solid was washed with hexane (5 mL x 2) and then dried in vacuo to give (6aR,9R)-5-bromo-N4-cyclopropyl-N9-
((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-
6a,7,8,9-tetrahydroindolo[4,3-fg]quinoline-4,9(6H)-dicarboxamide, HCl (analog 688, 546mg, 0.71 mmol, 92% yield) as a HCl salt. 1H
NMR (400 MHz, DMSO-d6) d 11.70 (s, 1H), 9.58 (s, 1H), 8.72 (d, J = 3.5 Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.17
(s, 1H), 7.16 (d, J = 8.0 Hz, 1H), 6.42 (s, 1H), 4.43 – 4.34 (m, 1H), 4.32 (dd, J = 7.8, 5.6 Hz, 1H), 4.22 (br s, 1H), 3.77–3.70 (m, 2H), 3.51 –
3.27 (m, 4H), 3.16 – 2.98 (m, 4H), 2.84–2.80 (m, 1H), 2.22 – 1.53 (m, 8H), 1.04 (d, J = 6.7 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H), 0.88 (d, J =
6.6 Hz, 3H), 0.78–0.73 (m, 5H), 0.63 (t, J = 3.5 Hz, 2H); LC-MS (Method 2): tR = 4.49min, m/z (M+H)
+ = 737 and 739; HRMS calculated
for C36H46BrN6O6 (M+H)
+: 737.2657 and 739.2644, found: 737.2677 and 739.2665.




Dopamine receptor BRET assays
Bioluminescence Resonance Energy Transfer (BRET) based dopamine receptor G protein engagement assays were conducted as
previously published (Bonifazi et al., 2017, 2019). G protein engagement assay uses Renilla luciferase-fused dopamine receptor and
mVenus-fused Ga, specifically D1R-Rluc Gs-mVenus, D2R-Rluc Gi1-mVenus, D3R-Rluc Gi1-mVenus, D4R-Rluc Gi1-mVenus, and
D5R-Rluc Gs-mVenus for each pair. Transfected HEK293T cells were harvested, washed, and resuspended in PBS. Approximately
200,000 cells/well were distributed in 96-well plates, and 5 mM coelenterazine H (substrate for BRET) was added to each well. The
BRET signal was determined as the ratio of the light emitted by mVenus (520-550nm) over RLuc (460-490nm) in Pherastar FSX (BMG
Labtech). Results are calculated for the BRET change (BRET ratio for the corresponding drug minus BRET ratio in the absence of the
drug). In parallel, the fluorescence of the acceptor was quantifiedwith excitation at 485 nm and emission at 520 nm for 1sec recording
to confirm the constant expression levels across experiments.
D2 Arrestin assay
CHO-K1 cells expressing DRD2 (long isoform) tagged with a ProLink sequence and b-arrestin fused to the Enzyme Activator protein
(DiscoveRx) were seeded in 1536-well plates at 2000 cells per well, 3 mL volume of assay medium. Plates were covered with a
Breathe-Easy sealing film and incubated in a 37C incubator (5% CO2, 95% RH) overnight. Compounds were pin-transferred and
returned to the 37C incubator for 90 min. 1.5 mL of detection reagent was added to each well and the plate was incubated at
room temperature for 60 min. Luminescence was detected on a ViewLux microplate imager, equipped with clear filters.
QUANTIFICATION AND STATISTICAL ANALYSIS
As described in figure legends, the statistical analyses were performed using the two-tailed unpaired Student’s t test, One-way
ANOVA with post hoc Dunnett’s multiple comparison test, Two-way ANOVA with post hoc Sidak or Tukey multiple comparisons
test using GraphPad Prism 8 (GraphPad Software). p < 0.05 was considered statistically significant. P value ranges are indicated
by asterisks in figure legends. Experiments were repeated independently multiple times and similar results were obtained. The
mean and error are noted for each dataset.
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1- Plate SH-SY5Y-GLuc-ASARTDL stable cells in 
half of wells (1500 cells per well, 5 µl volume).
2- Incubate 4 h and pin with 23 nL DMSO.
3- Incubate overnight and add 300 nM Tg or 
vehicle.
4- Collect medium from half of wells, pool, spin to 
pellet cells, and redistribute to empty wells (medium 
only).
5- Inject substrate into wells (red outline) and read
luminescence.  See panel B for results.
6- If substrate crosses membrane, then wells 
containing cells should exhibit increased signal.
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Figure S1:  Development and validation of SERCaMP assay for HTS.  Related to Figure 1.  (A) Experimental 
approach to determine source of luminescence in SERCaMP assay following direct addition of substrate to wells 
containing cells. (B) Most of the GLuc-SERCaMP luminescence is attributable to extracellular (secreted) reporter, 
with minimal contribution of intracellular protein. (C)  Assay statistics for 1536-well SERCaMP assay across 56 
plates.  (D)  Cycloheximide, an inhibitor of protein synthesis, was identified in counterscreen using a constitutively 
secreted GLuc.  (E)  Bortezomib, a proteasome inhibitor, was identified in counterscreen for viability using 
CellTiterGlo assay (Promega).   Bortezomib was included as a positive control in follow-up plates, and activity 
across eight plates is shown.  (F)  Venn diagram summarizing the number of compounds flagged in the 
constitutively secreted GLuc and viability counterscreens.  Twenty-one compounds were active in both 

























































































































































































Figure S2:   Counterscreens for five hit compounds from primary screen.   Related to Figure 2.  (A)  The five 
compounds identified in the qHTS campaign do not inhibit general secretory function.  SY5Y-GLuc-(NoTag) cells 
were treated with compounds for 16 h followed by 4 h with 100 nM Tg.  Medium was collected and GLuc activity 
was measured (mean ± SEM, n ≥ 3 independent experiments).  (B)  Effects on cell viability were assessed after 24 
h in the presence of 100 nM thapsigargin (mean ± SEM, n ≥ 3 independent experiments).   Luminescence values 
are normalized to a vehicle (no Tg) control.   (C-G) Dose-response data for 5 compounds when added 30 min prior 
(black symbols, dotted curve) or 16 h prior (colored symbols, colored curves) to thapsigargin administration.  
Luciferase was measured in the medium 4 h after 100 nM thapsigargin.  
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Figure S3: Support data for UPR analysis. Related to Figure 3.  (A)  Control reporter (to match UPRE reporter), 
which contains only minimal promoter and no UPR elements (minP::secNLuc), is not affected by compound 
treatment (mean ± SEM, n ≥ 3 independent experiments).  (B)  RT-PCR analysis of BiP, ERdj4, and ASNS 
transcript levels following a 16 h treatment with 30 µM compounds in the absence of thapsigargin (2-ddCq ± upper 
and lower limits, n=3, no significant differences detected with one-way ANOVA for each gene).  






















3.95 4.26 4.85 5.25 4.54

















































































Tg + 20µM 
Tg only 
Tg + 20µM 
4 hours 6-8 hours
bromocriptinebromocriptine
Tg only
Tg + 30µM 
Tg only 
Tg + 30µM 









































Figure S4: Models of ER/SR calcium depletion in primary muscle cells, doxycycline-induced WFS1 
knockdown, and oxygen-glucose deprivation.  Related to Figure 4.    (A, B) GLuc-SERCaMP release (A) 4 h 
and (B) 6-8 h-post thapsigargin treatment following 20 µM bromocriptine, 30 µM dantrolene, or vehicle pre-
treatment for 30 minutes (mean ± SEM, n= 8-16 wells/treatment). (C)  Wfs1 knockdown induces release of esterase 
activity, an endogenous SERCaMP reporter, indicative of ER calcium depletion.  Secreted esterase activity was 
measured in the medium 48 h after tetracycline treatment using a fluorescent substrate (mean ± SD, n=21 wells, 
***p<0.001).  (D) INS-1 832/13 pTetR TO shWFS1 cells were plated in 1536-well plates at various densities and 
treated with 2 µg/mL doxycycline for 48 h.  Caspase 3/7 activity was measured using a Caspase-Glo 3/7 assay 
(mean ± SD, n=64 wells).  Signal-to-background and Z-factor are indicated. 1000 cells per well was selected for 
subsequent experiments. (E)  Timelines for the oxygen-glucose deprivation paradigm. (F)  Secretion of MANF, an 
ERS-containing protein, was measured after OGD (16 h hypoxia plus 24 h normoxia) by HTRF assay (mean ± SD, 
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Figure S5.  Bromocriptine and ERS reporters.   Related to Figure 5.  (A)  Timelines for thapsigargin and 
oxygen-glucose deprivation models examining ERS-reporter proteins in transiently transfected cells.  (B) A 
comparison of the ability of 30 µM dantrolene (mean, n=6, 2 independent experiments) and 20 µM bromocriptine 
(mean, n=9, 3 independent experiments) to inhibit GLuc-ERS release in SH-SY5Y cells following 8 h treatment 
with 200 nM thapsigargin. (C) Secretion of GLuc-ERS reporters 24 h after a 16 h exposure to hypoxia with 20 µM 
bromocriptine (mean ± SEM, n=3). Secretion is shown as a fold change relative to normoxia controls treated with 
vehicle. 
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Figure S6:  GPCR activity of bromocriptine and agonists. Related to Figure 6.  (A) Effect of diverse D2R 
agonists on GLuc-SERCaMP secretion.  Compounds were added for 16 h prior to a 4 h incubation with 100 nM 
thapsigargin.  GLuc SERCaMP was measured in the medium (mean ± SD, n=18).  (B-E) Compound activities at 
the other dopamine receptor subtypes were measured using the G protein engagement BRET assays (D1R-Gs, 
D3R-Gi1, D3R-Gi1, and D5R-Gs).  G protein coupling for corresponding dopamine receptors was measured after 
10 min of drug incubation. While bromocriptine has partial activities at D1R, D3R, and D5R, the extent of efficacy 
for the analogues is much weaker than bromocriptine.  (F-O) Dose-response activation of GPCRs by bromocriptine 
versus analog 688.  Receptors were chosen based on single dose profiling of 320 GPCRs with 3 µM analog 688, 
see Table S3.  (P)  Cell viability in response to OGD is improved by bromocriptine and analogs (n=24, *p<0.05, *** 
p<0.001, two-way ANOVA with Dunnett’s multiple comparisons test).  (Q)  Secretion of MANF in response to OGD 





































































































































































Figure S7: Rat MCAO model of stroke and murine diet induced obesity model.  Related to Figure 7.  (A) 
Infarction area measured from TTC stained 2 mm rat brain slices prepared at 2 days following stroke with vehicle or 
dantrolene (60 nmol in 20 µl) administered i.c.v. 15 min prior to 60 min MCAO.  (B) Total infarct volume and (C) body 
asymmetry were both attenuated by treatment with dantrolene.  Data are mean +/- SEM (n=6 per group).  Statistical 
differences are based on two-way ANOVA, ***p<0.001 drug effect (A) and Welch’s t-test, *p<0.05 (B, C).   (D, E)  
Adult male mice were fed a high fat diet for eight weeks.  At end of eight weeks, animals were injected daily (i.p.) with 
vehicle, bromocriptine (12 mg/kg), and analog 688 (12 mg/kg) for 3 weeks while continuing on the high fat diet.  (D) 
Fat mass and (E) lean mass showed no significant changes in response to drug treatments.  (F) The average animal 
mass steadily increased over the duration of the experiment with no significant effect of drug.   (G)  The cumulative 
energy expenditure during the 3 weeks of drug delivery was increased by bromocriptine injection relative to vehicle 
and analog 688 injections (Data are mean +/- SD, *p<0.05, **p<0.01, one-way ANOVA followed by Tukey post hoc 
multiple comparisons test).  























































































Figure S8:  Activity of compounds related to bromocriptine and dextromethorphan.   Related to Figures 2 
and 6.  (A)  SIGMAR1 agonists do not uniformly inhibit GLuc-SERCaMP. Cells were treated with compound for 16 
h followed by 4 h of 100 nM Tg.  Medium was collected and GLuc-SERCaMP activity measured (mean ± SD; n = 
6 wells).  (B)  SIGMAR1 antagonists were measured as described in panel A (mean ± SD; n = 6 wells).  (C)  The 
LSD-like portion of bromocriptine does not inhibit GLuc-SERCaMP release.  Cells were treated with 38 uM of 
each compound for 16 h followed by 4 h of 100 nM Tg.  Medium was collected and GLuc-SERCaMP activity was 
measured (mean + SD; n = 3 wells).
